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ABSTRACT
Periodontal disease is an inflammatory disease caused by polybacterial infection
and inflammation plays key role that associates periodontal disease with different
systemic diseases including diabetes and cardiovascular diseases. The main objective of
this study is to evaluate and explore the association of serum IgG antibodies in four
distinct clusters that were formed empirically from species specific 19 periodontal
antibody titers with T2DM and pre-diabetes adjusting for known confounders such as
age, sex, race-ethnicity, income to poverty ratio, education, smoking and drinking
alcohol, BMI, WC, physical activity, missing teeth, dentist visits and other nutritional
factors.
From the first aim, we formed 4 clusters empirically using cluster analysis from
19 periodontal antibody titers and named it as Orange-Red, Red-Green, Yellow-Orange,
and Orange-Blue based on Socransky’s grouping scheme. Using the priory study model,
theoretically we made 3 groups i.e. Etiologic, Putative and Health related groups from 11
periodontal bacteria antibody. On the full adjustments for these known confounders, our
finding showed that Orange-Red cluster that included P gingivalis and Prevotella sps
were positively associated in moderate level with diabetes but not with pre-diabetes.
However, the Red-Green cluster which contained T denticola, T forsythia, A
actinomycetemcomitans and others (as shown in Flow chart 1) were inverse but
significantly associated to diabetes. The Orange-Blue cluster scores that included A.
naeslundii and E. Nodatum showed an inverse relation to diabetes and pre-diabetes in the
v

crude analysis but that was attenuated after adjustment [diabetes: OR 0.935 (0.8691.007), pre-diabetes OR: 0.987 (0.944-1.032) . The Yellow-Orange cluster that included
majority of Steptococcus sps were not found to be associated with diabetes or prediabetes. With the same approach, we found the significant positive association of
etiologic group with pre-diabetes among the association with the 3 groups.
In our second aim, we explored the possible interaction between serum IgG antibodies
and clinical periodontal destruction (as assessed by clinical attachment loss and pocket
depth) in association to diabetes. We found that the tertile of pocket depth modified the
association of Orange-Blue cluster with diabetes upon the full adjustment for the known
confounders.
In our third aim, we measured the extent of the association between empirically defined 4
clusters and theoretically defined 3 groups with each of the five key components of
cardiovascular risk factors i.e. hypertension, hypertriglyceridemia, low HDL-cholesterol,
central obesity, and elevated plasma glucose and also the MetS. We found no significant
association with any of these components and MetS but the elevated plasma glucose.
Elevated Orange-Red clusters was positively associated whereas Orange-Blue was
inversely but significantly associated with elevated plasma glucose. The association
became more prominent when the elevated plasma glucose greater than or equal to 110
mg/dl.
These findings show that specific periodontal antibody serological markers may be used
as predictor of systemic health mainly the diabetes status.
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CHAPTER 1
INTRODUCTION
1.1. Statement of Problem
Periodontal disease [PD] is a persistent polybacterial infection causing chronic
inflammation in periodontal tissues (Heller et al. 2012).It is present in up to 1 in 3 adults
(Dye 2012) and is characterized by local and systemic inflammation, formation of deep
periodontal pockets and destruction of connective tissue attachment , which may
eventually lead to tooth loss (Preshaw et al. 2012). Since the onset of disease (dental
carries or PD) is usually delayed for prolonged periods of time after initial colonization
by pathogens and the source of infection is often endogenous bacteria and initial
colonization may persist for years before the development of clinical signs and
symptoms, PD is also a hidden and neglected disease. However systemic inflammation
resulting from periodontitis has been found to be associated with several chronic
inflammatory diseases such as diabetes, vascular disease, and metabolic syndrome
[MetS] and is increasingly getting attention.
Although, PD is a polybacterial infection, majority of such association studies
have used indirect method to access the periodontal destruction (such as gingivitis
bleeding, tissue destruction, gum bleeding, pocket depth or attachment loss) to assess
periodontal disease. The problem in using these clinical parameters to measure the
periodontal destruction and study with systemic diseases is that these indirect methods
cannot measure the systemic effect evoked by these periodontal bacteria challenges. In
1

periodontal literature, the direct microbial measures of bacterial challenges or host
response to periodontitis with these systemic disease are understudied (Lockhart et al.
2012, Demmer et al. 2012, Lalla and Papapanou 2011, Desvarieux et al. 2010).
Recently, the longitudinal and cross-sectional findings from the Oral Infections
and Vascular Disease Epidemiology [INVEST] study (Desvarieux et al. 2005,
Desvarieux et al. 2013) have shown an association with mean carotid artery thickness by
clusters of periodontal bacteria that were classified as etiologic, putative or periodontal
health related. The etiologic group (Actinobacillus actinomycetemcomitans, Tannerella
forsythensis, Porphyromonas gingivalis ,and Treponema denticola) was strongly
associated with increased intima-media thickness in the carotid artery. The putative group
included Campylobacter rectus, Prevotella intermedia, Micromonas
(Peptostreptococcus) micros, Eikenella corrodens, Fusobacterium nucleatum while
Actinomyces naeslundii and Veillonella parvula were present in the healthy periodontal
group.
In the direct assessment of periodontal disease, serological markers such as
elevated serum Immunoglobulin A (IgA) or Immunoglobulin G (IgG) levels against those
periodontal bacteria (Darveau 2010) can measure host disruption of homeostasis. Studies
have reported that elevated antibody titers to some periodontal bacteria are highly
correlated with extent and severity of periodontitis while some are associated with the
healthy periodontal status. Elevated IgA suggests periodontitis that is in the active phase
while elevated IgG generally suggests past exposure to that specific periodontal bacteria.
Numerous studies (Holmlund et al. 2011, Pussinen, Alfthan, et al. 2007, VilkunaRautiainen et al. 2006, Pussinen et al. 2005, Pussinen, Jousilahti, et al. 2003) have used
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these serological markers to assess periodontal disease and measure the relationship with
other chronic diseases, particularly vascular diseases(Pussinen, Paju, et al. 2007, Darveau
2010)(Pussinen, Paju, et al. 2007, Darveau 2010). The clear understanding of the
association of serological markers with the systemic outcomes is very important to
understand the extent to which the different groups of periodontal pathogens may
stimulate immune response in chronic inflammatory disease activity and how these
periodontal antibody responses are related to systemic outcomes. Additionally, using
serological markers to assess the periodontal relationship with systemic outcomes could
be the best way because it measures the direct and cumulative life time systemic effects
evoked by the periodontal bacteria.
In this dissertation, we will evaluate the association of serum IgG antibodies
against periodontal bacteria with the systemic outcomes mainly type 2 diabetes mellitus
(T2DM), and MetS. We used the third National Health and Nutritional Examination
Survey (NHANES III 1988-1994) which is a complex, stratified, multistage probability
sample designed to provide prevalence estimates describing the health and nutritional
status of the civilian, non-institutionalized US population and which included people
from different racial/ethnic backgrounds. NHANES III survey has the periodontal IgG
antibody titers information for 19 periodontal bacteria which we linked with the
periodontal examination, blood laboratory reports and socio-demographic information in
40 years or older age groups.
1.2 Purpose and Objectives
In this dissertation, we cross-sectionally evaluated serum IgG antibody titers
against 19 periodontal organisms in relation to T2DM, pre-diabetes and MetS and its
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components in an adult population. Periodontal antibodies were grouped by two different
approaches. First, we used the data derived clustering approach (empirical approach) to
create different clusters, and second, we made three different groups based on a prior
study (INVEST study) by Desvarieux et al (2005) (theoretical approach). We
hypothesized that antibody clusters against periodontal bacteria were associated with
diabetes, pre-diabetes and MetS as PD and these systemic outcomes are interrelated.
Aim1: To cluster the 19 species- specific antibody titers against periodontal pathogens
empirically and theoretically into distinct groups and measure the strength of association
of these clusters in relation to T2DM, pre-diabetes, and normal plasma glucose levels.
Research question 1.1: What are the clusters obtained from species specific 19 serum IgG
antibodies titers?
Research question 1.2: What are the characteristics of individuals in the tertiles of each
antibody cluster?
Research question 1.3: What is the relationship between serum antibody titers against
periodontal pathogens grouped by empirical and theoretical approaches and type 2 DM,
pre-diabetes and normal plasma glucose levels?
Hypothesis: We expect to find out the strength of association of immune response to
periodontal antibodies in relation to T2DM, pre-diabetes, and normal.
Aim 2: To investigate the joint association of severity of periodontal destruction (as
assessed by clinical attachment loss (CAL) and pocket depth) and antibody clusters in
relation to T2DM and normal plasma glucose.
Research question 2.1: What are the profile characteristics of individuals across tertiles
of clinical periodontal measures?
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Research question 2.2: What is the relationship between serum antibody clusters and
T2DM, and normal glucose stratified and jointly classified by the tertiles of clinical
attachment loss?
Research question 2.3: What is the relationship between serum antibody clusters and
T2DMT2DM, and normal glucose stratified and jointly classified by the tertiles of pocket
depth?
Hypothesis: We expect that the strength of associations varies within strata of periodontal
destruction.
Aim 3: To explore the association of serum antibodies titer clusters with selected risk
markers of cardiovascular disease i.e. MetS and each of its individual components.
Research question 3.1: Is there a cross-sectional association between clusters of antibody
titers, MetS and each of key components of MetS (hypertension, hypertriglyceridemia,
low high density lipoprotein (HDL)-cholesterol, central obesity, and elevated fasting
glucose)?
Research question 3.2: Is there a cross-sectional association between etiologic, putative
and health related groups of antibody titers, MetS and each of key components of MetS
(hypertension, hypertriglyceridemia, low HDL-cholesterol, central obesity, and elevated
fasting glucose)?
Hypothesis: We expect that the specific clusters or groups are associated with these
cardiovascular risk markers.
1.3 Significance of Research
One of the main goals of this research is to determine if the clusters or groups of
IgG antibody titers are associated with systemic outcomes as evidenced by T2DM and
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MetS and to examine the confounding or effect modifier role of clinical periodontal
measures in the association. There are numerous bacteria associated with periodontal
region as periodontal bacteria coexist in a biofilm. It is therefore difficult to isolate the
potential effect of a particular pathogen, and studies evaluating the effects of individual
organisms are prone to type 1 error (Wang et al. 2007). To overcome this limitation, we
have grouped the periodontal organisms together using both empirical and theoretical
approaches. The use of cluster analysis helps to minimize the bias and makes the
interpretation easier. Significant findings from both the approaches would provide the
additional information on this topic.
In the first aim, we used cluster analysis to group 19 IgG periodontal antibody
titers empirically and theoretically and evaluated these in relation to type 2 DM, prediabetes, and normal glucose. This will help in the interpretation of the relation between
IgG titers of periodontal bacteria and T2DM and pre-diabetes. In the second aim, we
examined the joint association between periodontal status based on CAL and Pocket
Depth and antibody groups in relation to T2DM and normal glucose. The findings of this
specific aim clarify the extent to which the associations between antibody titers to
periodontal pathogens and DM are modified by clinical periodontal destruction.
Similarly, the MetS defined as a cluster or the concurrence of abdominal obesity,
dyslipidemia, hypertension and hyperglycemia according to the consensus of the National
Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) and is
associated with a very high risk for cardiovascular diseases and diabetes mellitus
(Marchesini et al. 2004, Grundy et al. 2004). The knowledge of the extent of their
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association with the antibodies against periodontal disease will add to the information on
the systemic disease-periodontal disease relation.
1.4 Outline of the Study
Chapter 2 of this dissertation provides background information about T2DM and
pre-diabetes, periodontal disease, the relation between periodontal disease and systemic
disease, the relation between antibodies against periodontal disease and systemic disease,
and gaps in current knowledge. Chapter 3 is the manuscript for aim 1 ‘The relation
between Serum Immunoglobulin G (IgG) Antibodies against Periodontal Bacteria and
Type 2 Diabetes and Pre-Diabetes’. Chapter 4 is the manuscript for aim 2, ‘Effect
modification of the relation between serological periodontal markers and type2 diabetes
by periodontal pocket depth.’ Chapter 5 is the manuscript for aim 3, ‘Relationship
between serological markers of periodontal bacteria and metabolic syndrome and its
components’. Chapter 6 is an overall summary of the findings from this dissertation and
includes a strengths and limitations, clinical implications and recommendation to
clinician and public health professional, suggestions for future research, and conclusions.
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CHAPTER 2
LITERATURE REVIEW
2.1 Hyperglycemia: Diabetes and Pre-diabetes
Diabetes, the excess accumulation of glucose in blood has a negative impact on
mortality, morbidity, and quality of life through its long term complications, which
include damage and dysfunction of different major organs especially eyes, periodontal
region, heart, kidneys, nerves and brain(Zarowitz 2011). It has been declared as a global
public health threat to society (Yang et al. 2012, 2012).
“The American Diabetes Association (ADA) defines diabetes as a group of
metabolic diseases characterized by hyperglycemia resulting from defects in insulin
secretion or its action or both” (Zarowitz 2011). Clinically, diabetes is broadly divided
into four categories. Type 1 Diabetes Mellitus (T1DM) results from a B-cell destruction
that leads to an absolute deficiency of insulin. T2DM which is much more prevalent,
occurs when body cells cannot produce enough insulin or do not react properly to insulin.
A third category is specific diabetes due to other causes, such as genetic defect of B-cells
to produce insulin, genetic defects in insulin action, specific disease of pancreas, or
drug/chemical-induced diabetes. The fourth category is gestational diabetes mellitus
(GDM), which is diabetes diagnosed during pregnancy (Zarowitz 2011, 2012). Among
those who are diabetic, T1DM accounts for approximately 5-10% and is mostly
associated with children while T2DM accounts for 90-95% of diabetic cases and occurs
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predominantly in adults. Other categories prevalence is in very smaller percentage
compared to T1DM and T2DM.
The diagnostic criteria for diabetes developed by the ADA are based on any one
of four abnormalities: glycemic hemoglobin A1C % (HbA1C) ≥ 6.5%, fasting plasma
glucose (FPG) ≥ 126 mg/dl (0.7 mmol/l), random elevated plasma glucose (RPG) ≥ 200
mg/dl (11.1 mmol/l) with symptoms, or a 2 hour oral glucose tolerance test (OGTT) ≥
200 mg/dl (11.1 mmol/l) (Zarowitz 2011).
In 1979, the National Diabetes Data Group (NDDG) first introduced the concept
of a metabolic state intermediate between normal glucose homeostasis and diabetes,
called glucose intolerance (IGT). The expert committee on diagnosis and classification of
diabetes later extended this concept in 1997 by recognizing those individuals with
impaired fasting glucose (IFG). This intermediate stage [IGT and IFG] were referred as
pre-diabetes (Buysschaert and Bergman 2011). Pre-diabetes is a condition when glucose
level is not in the diabetic range but is too high to be considered as normal. Individuals
diagnosed with pre-diabetes are in increased risk for diabetes as well as cardiovascular
and possibly, micro vascular complications (Pour and Dagogo-Jack 2011). Data suggest
that 70% of patients with pre-diabetes will eventually develop diabetes (Tabak et al.
2012). According to the ADA clinical practice recommendations, current diagnostic
criteria for pre-diabetes are one of these three criteria. FPG: 100 to 125 mg/dL (5.6–6.9
mmol/L), A1C between 5.7%-6.4%, or 2-hour plasma glucose values in the OGTT of 140
–199 mg/dl [7.8 –11.0 mmol/l] (Tabak et al. 2012, Buysschaert and Bergman 2011).
Globally, the prevalence of diabetes and pre-diabetes has dramatically increased
with the increase in urbanization, population growth, aging, increasing prevalence of
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obesity and physical inactivity. According to the World Health Organization (WHO), the
prevalence of diabetes worldwide is 6.4 %, which varies from 10.2% in the Western
Pacific to 3.6 % in the African region (Shaw, Sicree, and Zimmet 2010). The prevalence
of diabetes has been consistently increasing since 1980 (Danaei et al. 2011). There were
an estimated 30 million diabetes cases world-wide in 1985, which increased to 135
million by 1995 (King, Aubert, and Herman 1998). The latest WHO estimate is 285
million in 2010 and has been projected to increase to 438 million by 2030 (Shaw, Sicree,
and Zimmet 2010). In the United States alone, 25.8 million (8.3 % of the US population)
are suffering from diabetes; around 35% of US adults aged 20 & above and 50% of aged
above 50 have pre-diabetes (Hhs and Ada 2003). The direct and indirect cost associated
with diabetes is becoming an enormous problem, due to its chronic nature, severity of
complications and the means to control them. In the United States, direct cost was $116
billion and indirect cost was $58 billion. Dietary change, insulin use, physical activity
and oral medication help to control diabetes. Further control of blood pressure, blood
lipids and other preventive care practices of teeth, eyes, skin, feet and kidneys helps to
prevent complications from diabetes (Zekry et al. 2012, Chudyk and Petrella 2011). In
order to offer better treatment, prevention and control modalities, a deeper understanding
of the etiology of diabetes and pre-diabetes is needed.
2.2 Periodontal Disease
Periodontitis is a polymicrobial chronic inflammation (Papapanou 2012, Preshaw
et al. 2012, Lalla and Papapanou 2011) and is the most common inflammatory disease
(Dye 2012) in adults. At the same time, it is an often neglected and hidden chronic
disease because of its slow progressive nature. Periodontitis is asymptomatic in early
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stages, and the tissue destruction that occurs during this stage is irreversible (Preshaw et
al. 2012).
There is no universally accepted case definition for periodontitis in
epidemiological studies (Papapanou 2012), hence the prevalence of periodontitis varies
depending upon the definition. The Centers for Disease Control and Prevention (CDC) in
partnership with the American Academy of Periodontology (AAP) recently published a
case definition of periodontitis. The total number of adults in the US with periodontitis
(i.e. sum of mild, moderate and severe forms) is 64.7 million adults, (47.2%), (8.7% mild,
30.0% moderate, and 8.5% severe) based on full mouth data. The prevalence is 19.5 %
when the two-site per tooth examination [as used by NHANES III periodontal
examination] or 27.1% when the three site half-mouth protocol was used in the sample of
NHANES 2009-2010 data (Papapanou 2012, Eke, Dye, et al. 2012). CDC/AAP defines
periodontitis when clinical attachment loss is ≥ 6mm and pocket depth is ≥ 4mm (Eke,
Page, et al. 2012). On the basis of NHANES III survey 1999–2004 data [in which the
three site half-mouth protocol was used], the prevalence of moderate to severe PD in the
United States was 5% among those age 35 to 49 years, 11% among those age 50 to 64
years, 14% among those age 65 to 74 years, and 20% among those age 75 years or over.
Moderate forms of the disease are even more prevalent, affecting 40 -60% of adults (Dye
et al. 2007). The combined expenditure for periodontal and preventive dental services in
the United States was estimated at $14.3 billion in 1999, whereas approximately $4.4
billion was spent for periodontal procedures. It should be noted that the prevalence of PD
varies according to socio-demographic and economic status (Papapanou 2012, Eke, Dye,
et al. 2012).
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With the advancement of molecular techniques (Socransky and Haffajee 2005,
Colombo et al. 2009) several bacterial complexes associated with the etiology of
periodontal healthy and diseased stage have been identified using the whole genome
DNA probes. The sub gingival biofilm in periodontal plaque constitutes more than 700
species (Socransky and Haffajee 2002), among which around 300 cultivable species have
been identified (Sugi et al. 2011). These species are not uniformly distributed in the
periodontal sites as multiple factors may impact the distribution of the nature of biofilm
(Haffajee, Teles, and Socransky 2006b, Socransky and Haffajee 2005, Haffajee et al.
2005) including the periodontal health or disease stage. Comparatively little research has
been done in this area but evidence is strong enough to suggest that the plaque
community in periodontal area could be a strong predictor of periodontal health or
disease stage (Haffajee et al. 2008).
Although many different bacterial species may participate in the destruction of
host periodontal homeostasis, three red complex periopathogens as described by
Socransky & Haffajee (Socransky and Haffajee 2002) namely, T forsythensis , P
gingivalis , P intermedia , T denticola were found to be strongly associated with disease
stage. Studies have revealed that these bacteria have the ability to impair innate immune
system (Rescala et al. 2010). Additionally, putative bacterial species which are
predominantly the orange complex bacteria such as C rectus, F nucleatum, M micros,
Eubacterium nodatum , and Prevotella nigrescens are also thought to play an important
role in shifting the plaque microbial community from periodontal healthy to diseased
stage(Haffajee, Patel, and Socransky 2008, Socransky and Haffajee 2002). Red and
Orange complex bacterial species are found significantly higher in periodontal disease
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stage (Haffajee, Teles, and Socransky 2006a). In contrast, members of Actinomyces,
yellow, green, purple complex bacteria and some other species are usually found in
periodontal healthy as well as diseased sites (Socransky and Haffajee 2002, 2005, Dye et
al. 2009).
It is generally accepted that periodontitis infection leads to humoral
immunological response which can be measured by different immunological markers
including antibodies such as serum or saliva IgG and IgA antibody to periodontal
bacteria. The increased IgA antibody level in saliva indicates persistent periodontal
infection while its presence in serum is not fully understood (Pussinen et al. 2005). Serum
IgG antibodies to periodontal bacteria are stable over time and explain that the individual
was exposed to that specific bacteria (Papapanou et al. 2004).
A recent study by Pussinen and team (Pussinen et al. 2011) in a nationally
representative sample of 1586 Finnish dentate subjects found that periodontal pathogen
Actinobacillus actinomycetemcomitans and P gingivalis carriage rather than periodontitis
determines the serum antibody level (Sugi et al. 2011). One case control study studied
IgG antibody titers to 12 periodontal pathogens as a marker to predict the recurrence of
periodontitis. They found that those who had higher elevated serum IgG antibody (Sugi et
al. 2011) titers to E corridens FDC 1073, P gingivalis SU63 and C rectus ATCC 33238
resulted in recurrent periodontitis.
However, the discrepancies in findings on the correlation between elevated
antibody titers to putative pathogens and severity of periodontal disease complicates the
criteria to identify the antibodies IgG as immunological marker. In addition, the nonpathogenic periodontal bacteria can also elicit the serum antibodies and even people with
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healthy periodontal status also harbor the serum IgG antibodies specific to periopathogens (Papapanou et al. 2001). Nonetheless, the intensity of serum IgG antibody to
nonpathogenic periodontal bacteria is very nominal and could be due to the certain level
of cross –reactivity to the common epitopes shared by periodontal bacteria (Dye et al.
2009). Further complication comes when some findings (Ozmeric 2004) support the
concept that the humoral immune response plays a protective role, for instance the
chronic periodontitis patients with greater pocket depths and more gingival inflammation
had paradoxically lower antibody titers to suspected periopathogens. More research is
needed to clarify and explore such discrepancies.
Periodontitis as well as periodontal microbiota are influenced by sociodemographic variables (Haffajee et al. 2005, Lopez et al. 2004, Dye and Thornton-Evans
2010, Dye and Selwitz 2005, Beltran-Aguilar et al. 2005, Lalla et al. 2004, Baelum et al.
2002), life style (Uzel et al. 2011, Bogren et al. 2007, Haffajee et al. 2005)(Uzel et al.
2011, Bogren et al. 2007, Haffajee et al. 2005), eating behaviors (Pussinen, Laatikainen,
et al. 2003, Ervin and Dye 2009), anthropometric measures(Desvarieux et al. 2010),
fitness (Haffajee and Socransky 2009, Roberts et al. 2002), diabetes mellitus and other
co-morbidities(Roberts et al. 2005, Dye et al. 2005), number of teeth (Sachdeo, Haffajee,
and Socransky 2008) and dental health (Dye et al. 2007). In nationally representative
samples of US adults from NHANES III survey (Vlachojannis et al. 2010) found that
dentate participants had higher elevated IgG antibody titers to A actinomycetemcomitans ,
and red complex species P gingivalis was twice as high in periodontitis than periodontal
healthy individuals. Also, Mexican American and Non –Hispanic Black were more likely
to have elevated serum antibodies than Whites.
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Antibiotic use affects the oral microbiota (Haffajee, Patel, and Socransky 2008,
Haffajee, Torresyap, and Socransky 2007, Socransky and Haffajee 2002) but its impact
on serum immunoglobulin has not been explored adequately. Nevertheless, a few
research findings (Papapanou et al. 2004, Darby, Mooney, and Kinane 2001, Alfakry et
al. 2011) have shown that there is long stability of serum IgG antibody to periodontal
bacteria even after successful periodontal therapy with antibiotics or scaling, the presence
of which markedly suggests past history of periodontal infection.
2.3 Correlation of Periodontal disease with other diseases
The contribution of periodontitis to a state of systemic inflammation is getting
considerable attention in recent times (Lalla and Papapanou 2011). Periodontal diseases
have long been associated with major chronic diseases such as diabetes and vascular
diseases.
2.3.1 Periodontal Disease and Diabetes/ Pre-diabetes
The relation between chronic periodontal diseases and diabetes has been studied
intensively since 1947 (Glickman 1947). Both the diabetes and periodontal disease are
multifactorial diseases, and the association is bidirectional i.e. the presence of one disease
tends to boost the other disease and precise management of either disease tends to assist
in the treatment of the other (Lalla and Papapanou 2011, Preshaw et al. 2012, Pradhan
and Goel 2011). Loe was the first to propose periodontal disease as the sixth
complication of diabetes in 1993 (Loe 1993) and ADA acknowledged that periodontal
disease is often found in diabetic cases in 2003 (Preshaw et al. 2012).
In the US NHANES III population, adults with an HbA1c level of ≥ 9% were
found to have a significantly higher prevalence of severe periodontitis than those without
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diabetes (OR 2.9; 95% CI 1.40-6.03) after controlling for age, ethnicity, education, sex
and smoking (Tsai, Hayes, and Taylor 2002). A recent 5 year prospective longitudinal
study in 2,973 non-diabetic participants from the study of health in Pomerania (SHIP),
revealed that participants with advanced periodontitis at baseline showed an
approximately fivefold higher increase in HbA1c after 5 years when compared to those
with no periodontitis at baseline, which suggest the impact of periodontitis on diabetes
(Demmer et al. 2010).
The outcome of a meta-analysis study from 49 cross-sectional and eight
longitudinal studies of the 2440 identified studies published between 1980 to 2007 found
that periodontitis is a risk factor of T2DM while more studies are needed to confirm the
harmful effect to T1DM (Chavarry et al. 2009). This is probably due to T1DM being
more prevalent in young children while middle aged men and women have increased risk
for periodontitis and T2DM (Merchant et al. 2011).
Glycemic control with decreased HbA1c levels has been an important marker of
decreased complications from diabetes. Several different meta-analysis (Teeuw, Gerdes,
and Loos 2010, Darre et al. 2008, Janket et al. 2005, Jones et al. 2007, Simpson et al.
2010) outcomes have indicated the reduction of HbA1c% (T1DM or T2DM) around
0.4% after effective periodontal treatment for at least 3 months. One meta-analysis
(Janket et al. 2005) of glycemic control after mechanical treatment of periodontal
diseases showed the weighted average 0.38% decrease in actual HbA1c level for all
studies, 0.66% when restricted to type 2 diabetic patients, and 0.71% if antibiotics were
given to them. Although none were statistically significant, clinical significance of these
results cannot be underestimated. The 2010 systemic review (Simpson et al. 2010) which
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included seven randomized clinical trials exclusively with type 2 diabetes was similar
[0.4% reduction of HbA1c; 95% confidence interval (CI) fixed effect -0.78% to -0.01%)]
to earlier meta-analysis results. Although these randomized clinical trials had
heterogeneity of data and low power for the statistical analysis, the 0.4 % HbA1c
reduction value has substantial clinical significance. Less potent classes of oral glucose –
lowering agents reduce HbA1c % level by 0.5-1% and other classes of oral agents (i.e.
insulin secretagogues) combined with other methods such as nutritional therapy and
physical activity increases HbA1c by 1-2% (Santos Tunes, Foss-Freitas, and NogueiraFilho Gda 2010).
Furthermore, many studies have revealed that presence of diabetes and
periodontal disease combined aggravating the complications of macrovascular and
microvascular diseases. The recent prospective study of the Gila River Indian community
with 529 participants unfolded the findings that cardio-renal mortality (combination of
ischemic heart disease and diabetic nephropathy) was three times more likely in diabetics
with severe periodontitis compared to diabetics without severe periodontitis after
adjusting for age, sex, diabetes duration, HbA1c, macroalbuminuria, BMI, cholesterol,
hypertension, electrocardiogram abnormalities, and smoking (Shultis et al. 2007).
Prospective diabetes studies (Stratton et al. 2000, Khaw et al. 2004) have revealed the
finding that every 1% reduction in HbA1c resulted in a 21% reduction in the risk for any
end point related to diabetes, 21% reduction in deaths related to diabetes, 14% reduction
in myocardial infarction and a 35% decreased risk of microvascular complications.
There is a very limited knowledge about the periodontal bacterial profiles or
antibody response patterns that are distinctly associated with T1DM or T2DM cases and
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no large epidemiological studies have focused on this area. In the few studies involving
culture of oral bacteria, P gingivalis, P intermedia and Capnocytopha species were found
to be significantly higher in those with diabetes than non-diabetic participants (Zambon et
al. 1988, Mealey 1999, Sbordone et al. 1998). Among children with T1DM, it was found
that level of E nodatum antibody was significantly higher in diabetic patients while no
difference was seen in serum IgG levels to 11 other bacteria (Lalla et al. 2006). These
findings suggest apparent lack of significant differences in potential pathogens in diabetic
and non-diabetic participants; however it should be noted that these studies are limited
with respect to sample size and diversity of bacteria assessed (Lalla and Papapanou
2011). More detail literature review related to epidemiological studies evaluating the
relation between periodontal microorganisms with diabetes and periodontitis are shown
in Table 2.1.
Inflammation is believed to be the common link which affects glycemic control,
insulin resistance and periodontal damage. The mechanism is not clearly understood, but
it includes immune functioning, cytokine and neutrophil activities. More research are
needed to understand the biological pathway that links between the periodontitis and
diabetes (Preshaw et al. 2012). The association of these two chronic diseases provides a
perfect example of a cyclic association in which systemic diseases predisposes an
individual to oral infection and once the oral perio-pathogens are established, the
systemic disease is exacerbated (Pradhan and Goel 2011). Figure 2.1 shows the
bidirectional relationship of periodontal infection and diabetes contributing to insulin
resistance. The detail pathological mechanism of periodontitis and diabetes association
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can be found elsewhere (Lalla and Papapanou 2011, Santos Tunes, Foss-Freitas, and
Nogueira-Filho Gda 2010, Pradhan and Goel 2011).
2.3.2 Periodontal Disease and Cardiovascular markers including MetS
Independent of diabetes, increasing epidemiological evidence suggests an
association of periodontal disease and atherosclerotic vascular disease (ASVD) due to its
systemic inflammation. The American Heart Association (AHA) (Lockhart et al. 2012)
recently investigated the independent association of periodontal disease and ASVD
reviewing all the available data from 1950 to 2011. The AHA Scientific committee
reviewed 473 out of 537 studies that met the inclusion criteria of the association between
periodontal disease and any cerebrovascular, peripheral vascular or cardiovascular
disease. Observational studies supported an association between periodontal disease and
ASVD independent of known confounders (age, diabetes mellitus, and smoking);
however causation was not supported. Periodontal intervention helps in a reduction in
systemic inflammation and endothelial dysfunction but there is no evidence to suggest
intervention prevents ASVD or modify its outcomes.
Out of hundreds of studies that have investigated the association with
cardiovascular diseases, very few studies have explored the direct linkage with
periodontal microbes or host immune response to these periodontal microbes. Periodontal
pathogens such as P gingivalis, A actinomycetemcomitans, P intermedia, T forsythia, and
Streptococcus mutans have been found to be associated with atherosclerotic plaques.
Desverieux et al (Desvarieux et al. 2005) assessed 11 known periodontal microorganisms
from 657 dentate subjects enrolled in INVEST and found that overall bacterial burden
was related to carotid artery intima-media thickness (IMT) after adjusting for age, race,
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gender, education, BMI, smoking, diabetes, blood pressure, and Low density lipoprotein
(LDL) and HDL cholesterol. Adjusted mean IMT values of etiologic bacterial burden
with four organisms, P gingivalis, A actinomycetemcomitans, T forsythia and T denticola
were found to have significant increasing trend across tertiles. Spahr et al, 2006
investigated an association of combined colonization of five periodontal bacteria [P
gingivalis, A actinomycetemcomitans, P intermedia, T forsythia and T. denticola to
Cardiovascular diseases (CHD) and revealed that for each 1 unit log increase in total
burden, the OR increased by 1.83 times (95% CI 1.23-2.71).
Pussinen et al in Finland investigated an association of combined serum IgG
antibody titers of P gingivalis and A actinomycetemcomitans to ASVD and found
significantly higher titers [Hazard Ratio (HR):1.87 (1.13-3.08)]. In a separate study
(Pussinen, Jousilahti, et al. 2003), the same team investigated serum IgG antibody titers
of P gingivalis and A actinomycetemcomitans individually to CHD. The association was
significant with each of high titers of bacteria [Relative risk (RR) for high A
actinomycetemcomitans: 2.0 (1.2-3.3) and RR for P gingivalis: 2.1 (1.3-3.4)] after
adjusting for potential confounders. Currently, attention has been paid to the applicability
of anthropometric markers to measure diabetes complications, cardiovascular risks and
their control.
MetS is associated with a very high risk for cardiovascular diseases and diabetes
mellitus (Marchesini et al. 2004, Grundy et al. 2004). In the NHANES III study in US
population, participants older than 45 suffering from severe periodontitis were 2.31 times
(95% CI 1.13-4.73) more likely to have MetS than unaffected individuals after adjusting
for confounders (D'Aiuto et al. 2008). Poor periodontal health conditions were found in
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patients with diabetes. Periodontal disease association with MetS was found true in other
study populations independent of other risk factors (Li et al. 2009, Han et al. 2012, Kwon
et al. 2011, Yu et al. 2012); however no recent studies have investigated the role of
periodontal microbiota with MetS.
Waist circumference (WC) is recognized as one of key component of MetS and
also provides a better measurement of cardiovascular risk and obesity. WC represents
central adiposity and is measured using a steel measuring tape to the nearest 0.1 cm at the
high point of the iliac crest at minimal respiration when the participant was in a standing
position (Wood, Johnson, and Streckfus 2003). A recent meta-analysis revealed a
significant association between periodontitis and obesity (OR 1.35; 95% CI 1.23, 1.47),
suggesting that abdominal obesity is independently associated with periodontitis(Chaffee
and Weston 2010). Evidence is increasing for an association of gut microbiota with
obesity (Le Chatelier et al. 2013) while no study has explored the association with
periodontal microbiota.
There is evidence that supports a correlation of periodontitis with other markers of
MetS such as hypertension(Desvarieux et al. 2010, Bonato et al. 2012, Vidal et al. 2009),
LDL (Itabe 2012), HDL (Pussinen, Jauhiainen, et al. 2004, Wu et al. 2000), Total
Cholesterol (TC) (Wu et al. 2000), and Triglycerides (TG) (Banihashemrad,
Moeintaghavi, and Rafighdoost 2008, Cutler and Iacopino 2003, Morita et al. 2004)
individually but none of epidemiological studies have investigated the role of periodontal
microbiota or the host response with these metabolic complication markers.
Since both the periodontitis and MetS are associated with systemic inflammation and
insulin resistance, these two diseases may be linked through a common
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pathophysiological pathway (D'Aiuto et al. 2008). Oxidative stress may act as a potential
common link to explain relationships between each component of MetS and periodontitis.
Both conditions show increased serum levels of products such as elevation of C-reactive
protein and fibrinogen derived from oxidative damage, with a pro-inflammatory state
likely influencing each other bidirectionally (Bullon et al. 2009).
2.4 Gap in the Knowledge
The possible association between periodontal disease and other diseases has been
studied extensively assessing periodontitis with self-reported periodontal disease or
clinical periodontal examination, but periodontal microflora associated with periodontitis
as a marker of periodontal disease is understudied. There are very few large studies
(Pussinen et al. 2011, Papapanou et al. 2000) which have combined clinical, bacterial and
immunological data which could elucidate the possible role of these periodontal bacteria
in systemic immune response and periodontitis. The need to understand the periodontal
microbiota profile and its immunological marker is important primarily to measure direct
systemic activity, but also to comprehend increasing evidence of periodontal disease
being a potential modulator of diabetes mellitus(Dye and Genco 2012, Lalla and
Papapanou 2011), obesity (Chaffee and Weston 2010, de Castilhos et al. 2012,
Jagannathachary and Kamaraj 2010), atherosclerosis (Papapanou and Trevisan 2012,
Lockhart et al. 2012, Behle and Papapanou 2006, Desvarieux et al. 2005, Beck et al.
2001), other vascular diseases (Pussinen, Alfthan, Tuomilehto, et al. 2004, Pussinen,
Alfthan, Rissanen, et al. 2004, Pussinen, Jousilahti, et al. 2003, Papapanou 2009, Beck et
al. 2005), preterm labor (Pussinen, Paju, et al. 2007, Albert et al. 2011, Michalowicz,
Novak, et al. 2009, Michalowicz, Hodges, et al. 2009, Jarjoura et al. 2005) and different
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other systemic diseases(Demmer et al. 2012, Michalowicz et al. 2011, Desvarieux et al.
2010, Behle et al. 2009, Beck et al. 2005, Zoppini et al. 2012).
In this dissertation, we analyzed serum IgG antibodies against 19 periodontal
bacteria from the NHANES III survey dataset. The NHANES III dataset provided a
unique opportunity to explore these relationships because this survey has data on
periodontal examination, laboratory assessment of serum IgG antibodies to 19 different
periodontal bacteria, socio-demographic, anthropometric and nutritional information in
large number of US adult’s participants. The variables that were used from these different
NHANES III sub datasets are shown in Table 2.2. Figure 2.2 depicts the phyla (and
groups as defined by Socransky and Haffajee (Socransky and Haffajee 2002, 2005) of 19
periodontal bacteria species to which serum IgG antibodies were identified and measured
by checker board DNA-DNA hybridization in NHANES III survey (Papapanou et al.
2001).
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Table 2.1- Epidemiological studies evaluating the relation between periodontal
microorganisms in individuals with diabetes or pre-diabetes

N
o

1

Author ,
Year
title and
publication
Study
design
Zhou et al
(2013).
Investigatio
n of the
Effect of
Type 2
Diabetes
Mellitus on
Subgingival
Plaque
Microbiota
by HighThroughput
16S rDNA
Pyrosequen
cing.
PLoS One.;
8(4):
e61516.
Crosssectional
study

Purpose
Charac
of the study teristic
s of the
populat
ion
Subginival
biofilm in
different
groups of
periodontiti
s and
diabetes are
compared
within
different
groups.
They
included
non-diabetic
subjects
without
periodontiti
s (P-D-),
non-diabetic
subjects
with
periodontiti
s (P+D-),
type 2
diabetic
patients
without
periodontiti
s (P-D+),
and type 2
diabetic
patients
with
periodontiti
s (P+D+).

31
Chines
e
subject
s,
30-65
years
old
had at
least 20
teeth
without
any
clinical
signs of
oral
mucosa
l
disease
or root
caries

Method of
detecting
microorgani
sms
& Statistical
Analysis
16s rDNA
Pyrosequenci
ng

Findings

The
sequencing
depth was
similar
Wilcoxon
among
rank-sum test different
and Fisher’s sample
exact test
groups
although a
slightly
smaller
amount of
sequences
were
generated
from the
P+D- group.
The samples
in the
periodontitispositive
groups (i.e.,
P+D- or
P+D+) are
well
separated
from those in
the
periodontitisnegative
groups (i.e.,
P-D- or PD+) based on
the
unweighted
UniFrac
distances
28

Inferences
&
Limitations

These
findings
reflect that
the bacterial
compositions
in
periodontitis
and healthy
samples were
distinct.
Furthermore,
compositiona
l shifts in the
subgingival
plaque
bacterial
community
associated
with
periodontitis
also exist in
diabetic
patients.
small sample
size

measured at
the OTU
level
In the
subjects with
healthy
periodontium
, the
abundances
of three
genera
(Prevotella,
Pseudomona
s, and
Tannerella)
and nine
OTUs were
significantly
different
between
diabetic
patients and
their nondiabetic
counterparts.
In the
subjects
carrying
periodontitis,
the
abundances
of three
phyla
(Actinobacte
ria,
Proteobacter
ia, and
Bacteriodete
s), two
genera
(Actinomyces
and
Aggregatibac
ter), and six
OTUs were
29
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and chronic
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4. J Periodont
Res 2013;
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Case Only
study
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periodontiti
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Compare
Severe Subgingival
Among the
the sub
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small sample
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5. 36. Field et al.
7. (2012)
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and
Piracic
aba
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school,
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2007 to
Feb
2010.
Mean
age
group
were
slightly
higher
in
diabetes
group
[51.8
(4070)]
compar
ed to
non
diabetic
group
[47.8
(4162)].
Female
were in
higher
proporti
on in
diabetic
group
than
non
diabetic
.

in the
periodontal
pockets of
Non-DM
subjects (p <
0.05).
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Cultivation
subjects (A
who
actinomycete

A
No
actinomycete significant
mcomitans, F difference

Moreover,
some
phylotypes,
such as
Fusobacteriu
m nucleatum,
Veillonella
parvula, V.
dispar and
Eikenella
corrodens
were
detected
significantly
more often in
diabetic
subjects than
in
nondiabetic
subjects (p <
0.05).
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n and
quantificati
on of key
periodontal
pathogens
in patients
with type 2
Diabetes.
9. J Periodont
Res 2012;
47: 470–
478
10.
Matched
Case control
study

in selected
periodontop
athogens in
the sub
gingival
plaque of
diabetes
patients
using
TaqMan
quantitative
PCR

have
confirm
ed
T2DM
with
(n=9)
or
without
periodo
ntitis
(n=15)
were
recruite
d from
New
Castle
Dentist
Hospit
a, UK.
Age,
sex, and
smokin
g
statusmatche
d
control
nondiabetic
subjects
(with
periodo
ntitis
(n=12)
and
without
periodo
ntitis
(n=12)
were
recruite
d from
from
same
hospital
.

mcomitans, F
nucleatum
and P
gingivalis)
and
quantificatio
n by qPCR

nucleatum
and P
gingivalis
were present
in
significantly
different
quantities
and
One way
proportion
ANOVA
according to
Bonferroni
periodontal
post hoc tests disease status
but there was
Mann
no clear
whitney Udistinction
test
between
three
microbiota in
diabetes and
non diabetes
group.
However, P
ginivalis
were higher
in
periodontitis
(diabetic and
non diabetic
group) than
periodontal
healthy
subjects.
A
actinomycete
mcomitans
were found
in lower
quantities in
all
subgroups
while
F nucleatum
were
abundant in
all subgroups
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were
identified
between the
sub gingival
flora
between
T2DM and
non –diabetic
patients.
Limited no
of
microorganis
m.

Control
Patients with
T2DM were
recruited
who
currently
deemed
stable with
regard to
diabetes
symptoms by
their medical
practioner.

4

Majorit
y of
study
particip
ants
were
Whites
male
and Ex
or non
smoker
s, over
18
years of
age and
a
minimu
m of 20
teeth.
da Cruz
to evaluate
20
et al. (2008) the clinical
adults
Clinical and and
with
laboratory
laboratory
periodo
evaluation
changes 3
ntitis,
of nonmonths after of
surgical
full-mouth
whom
periodontal scaling and 10 were
treatments
root planing type 2
in type 2
in subjects
diabetes
Diabetes
with and
mellitus
patients.
without
who
J periodont, diabetes
require
79 :1150mellitus
d
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insulin
therapy
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(DM)
al followand 10
up
healthy
study (3
adult
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control
following
subjects
non(NDM)
surgical
with
periodontal
generali
therapy
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chronic

with no clear
distinction.

PCR analysis
of
subgingival
plaque
samples for
A.
actinomycete
mcomitans,
P.
gingivalis
and T.
forsythia
two-way
ANOVA
x2 test
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Periodontal
status
improved
following
treatment,
but no
changes in
HbA1c
Occurred.
Reductions
in the
frequency
of bacterial
recovery
occurred
over the 3
months, but
there were no
significant
differences
between the
two groups

Clinical and
laboratory
responses
were similar
in T2DM and
NDM groups
3 months
after fullmouth
scaling and
root planing.
Small
numbers
Uncontrolled
diabetes
subjects who
required
insulin
therapy

5

periodo
ntal
disease
were
recruite
d from
dental
clinic,
Univers
ity of
Campin
as,
Brazil
Age
ranged
from
30-70
years
and had
at least
20
teeth.
Subject
s were
evaluat
ed 3
months
(OctDec
2006)
Ebersole
comparison 39
et al. 2008
of sub
Hispan
Microbiolo gingival
ic
gic and
plaque
Americ
Immunolog samples and ans
ic
serum
with
Characterist antibody
T2DM,
ics of
levels to
and 24
Periodontal selected oral nonDisease in
microorgani diabetic
Hispanic
sms in
controls
Americans T2DM
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With
suffering
recruite
Type 2
Hispanic
d from
Diabetes
population. Brady
Green

DNA
checkerboard
hybridization
of plaque
samples,
and ELISA
analysis of
serum IgG
levels were
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two-way
ANOVA
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Similar
pathogens
were found
in
periodontitis
sites in
subjects with
and without
T2DM,
though
P.gingivalis,
A.
actinomycete
mcomitans
and
Campylobact

poor oral
hygiene,
site-specific
samples
should be
considered

J
Periodontol
Vol74 (4)

clinic,
Texas,
US in
1994
Mean
age of
diabetic
groups
54.2
(39-72)
while
non
diabetes
group
was
47.4
(33-68)
years.
Female
were in
higher
proporti
on in
diabetes
groups.
In
T2DM
group,
non
smoker
s were
27 out
of 39
and in
non
diabetic
non
smoker
s were
20 out
of 24.

Crosssectional

6

Makiura et
al. 2008
Relationshi
p of

assess the
relationship
between
serum

30
Japane
se
adults

er species
were found
more
frequently (p
< 0.05) in
subjects with
T2DM
compared to
those
without.
Also, serum
IgG
responses
were broadly
similar
between the
two groups,
apart from a
significant
elevation in
antibody to C
rectus in the
diabetic
subjects

Used
polymerase
chain
reaction
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It was
observed that
posttreatment, P.

The authors
postulated
that glycemic
control in

Porphyrom
onas
gingivalis
with
glycemic
level in
patients
with type 2
diabetes
following
periodontal
treatment.
Oral
Microbiol
Immunol
2008: 23:
348–351.
Prospective
longitudinal
study

glycemic
levels and
subgingival
microbial
profile
alteration
following
periodontal
treatment in
patients
with type 2
diabetes
mellitus.

(14
male
and 16
female)
sufferin
g from
chronic
periodo
ntitis
and
T2DM
were
recruite
d.

[PCR]
method,
The target
microorganis
ms were P
gingivalis,
A
actinomycete
mcomitans,
T
forsythensis,
T denticola,
and P
intermedia.

The age
of the
t-test
subjects
ranged
from 41
to 80
years
(mean
63.9 ±
9.4
years)
and
duratio
n of
DM
was
betwee
n 3 and
13
years
(8.5 ±
5.6
years),
with
HbA1c
values
ranging
from
6.0% to
10%
(7.11 ±
36

gingivalis
was detected
more
frequently in
those who
had
increased
HbA1c
values
compared to
those with
decreased
values
relative to
baseline, and
more
specifically,
P. gingivalis
with type II
fimbriae was
detected only
in patients
with an
increase in
HbA1c.

patients with
periodontitis
and diabetes
is potentially
influenced
by the
persistence
of P.
gingivalis,
particularly
clones with
type II
fimbriae,
following
treatment
Small sample
size
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Hintao et
al. 2007
The
microbiolo
gical
profiles of
saliva,
supragingiv
al and
subgingival
plaque and
dental
caries in
adults with
and without
type 2
diabetes
mellitus.
Oral
Microbiol
Immunol
22: 175–
181
Statified
Crosssectional
study

1.16%).
determine
Data
the effect of were
T2DM on
obtaine
coronal and d from
root surface 105
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patients
to
with
investigate
T2DM
some
and 103
factors
nonsuspected of diabetic
being
subjects
related to or in
interacting
Southe
with DM,
rn
that may be Thaila
associated
nd.
with coronal
and root
Among
surface
the
caries
T2DMs
, the
mean
duratio
n of
diabetes
was 8.7
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(SD
5.7).
The
mean
HbA1c
value in
the
group
was
8.5%
(SD
2.1) and
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from
5.6
to15.8
%.

17 bacterial
species using
the
Checkerboar
d
DNA–DNA
hybridization
method.
The chisquared test
(Bonferroni
correction)
The Mantel–
Haenszel
odds ratio
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Significantly
more
diabetic
subjects had
higher levels
of T
denticola, P
nigrescens, S
sanguinis, S
oralis and S
intermedius
in their
supragingival
plaque than
non-diabetic
subjects.
None of the
bacterial
species
tested in the
subgingival
plaque
samples
demonstrated
an
association
with T2DM
No
significant
difference
was found
for the
organisms in
saliva, oral
rinse and
subgingival
plaque
between the
two groups.

Possible
association
of T2DM
with some
specific
bacteria
Mixture of
insulin and
non-insulin
diabetes
patients.
When using
the
checkerboard
method in
patients with
poor oral
hygiene,
site-specific
samples
should be
considered.
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Yuan
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et al. (2001) detection

85% of
the
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receivin
g oral
antidiabetic
treatme
nt or
dietary
controls
only,
7.5%
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insulin
treatme
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7.5%
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treated
with a
combin
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insulin
and oral
antidiab
etic
agents.
Mean
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in
T2DM
and 53
in Non
diabtete
s group)
and sex
in both
groups
were
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proporti
on
105
PCR analysis No
significant
Taiwan detection
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No
difference

Detection
of putative
periodontal
pathogens
in noninsulindependent
diabetes
mellitus
(NIDDM)
and
nondiabetes
mellitus by
polymerase
chain
reaction.
J Periodont
Res 2001;
36: 18±24.

CaseControl
comparison

rates of 5
putative
periodontal
pathogens:
between
NIDDM
and nonDMadults
were
compared.
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adults
with
noninsu
lindepend
ent
diabetes
and 141
ageand sex
matche
d
nondiabetic
individ
uals
ages
ranging
from 28
to 78 yr
in the
NIDD
M
group
and 21
to 80 yr
in the
nonDM
group.
The
ratio of
male to
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in nonDM and
NIDD
M
groups
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1.39
and
1.33,
respecti
vely.

rates of A.
actinomycete
mcomitans,
P.
gingivalis, E.
corrodens, T.
denticola
and C.
albicans
Student's ttest
The chisquared test
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differences
in the
prevalence
rates of the 5
microorganis
ms between
the diabetic
and nondiabetic
individuals
was found

between
subgingival
microorganisms in
T2DM and
Non diabetic
group
Limited set
of
microorganis
ms
Age and sex
were not
adjusted
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Castrillon
et al (2013)
Occurrence
of red
complex
microorgani
sms and
Aggregatib
acter
actinomycet
emcomitans
in patients
with
diabetes
Journal of
Investigativ
e and
Clinical
Dentistry,
4, 1–7
Crosssectional
study.

Analyze the
occurrence
of red
complex
microorganisms
Aggregatib
acter
actinomycet
emcomitans
in patients
with
diabetes
(type 1 or
type 2)

60
patients
conﬁrm
ed
diagnos
is
(fasting
glucose
≥126
mg/dL
or
glycate
d hemoglobin
≥6.5%)
of type
I or II
DM
with a
previou
s (>2
years)
and
from
the
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l
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itario
San
Vicente
de Paul
(Medell
in,
Colomb
ia), and
62
patients
without
diabetes
from
the
School
of
Dentistr

Using PCR,
the
prevalence of
red complex
microorganis
ms
(P. gingivalis
, T. forsythia,
and
T. denticola)
and
A. actinomyc
etemcomitan
s were
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eriodontitis
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classiﬁed
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Academy of
Periodontolo
gy and Page
and Eke’s
classications

Periodontitis
patients
presented
with more
Bleeding on
Probing
(BOP) and
probing
depth ( PD)
than
systemicallyhealthy
patients
without
periodontitis
(P < 0.05).
The CAL
was
increased in
DM
periodontitis
patients
compared to
ND
periodontitis
patients, and
this
Kruskal–
difference
Wallis,
was
Mann–
statistically
Whitney Usigniﬁcant (P
test, and
< 0.05).
Fisher's exact In addition,
test
patients with
diabetes and
periodontitis
had lost more
teeth than
ND
periodontitis
patients P <
0.05)
Red complex
microorganis
ms were
40

Possible
association
of the
subgingival
microbiota
between
diabetic and
non-diabetic
patients.
In addition,
P. gingivalis
and
A. actinomyc
etemcomitan
s were
associated
with
periodontitis
in patients
without
diabetes and
patients with
diabetes,
respectively
Small sample
size
Limited
microorganisms

y at the
Univers
idad del
Valle
(Cali,
Colomb
ia)
They
particip
ated in
this
study
from
Februar
y 2011
to
March
2012,
Patients
had a
mean
age of
47
years,
and
there
were
more
females
than
males.

10 Vlachojanni
s et al.
(20100
Determinan
ts of serum

assess the
distribution
of elevated
antibody
titres to

>=40yearold
particip
ants

detected in
lower
frequencies
in patients
with
diabetes. The
detection of
A. actinomyc
etemcomitan
s was higher
in patients
with diabetes
and
periodontitis
compared to
systemicallyhealthy
patients
without
periodontitis
(P < 0.05).
P. gingivalis
was
associated
with
periodontitis
in nondiabetic
patients
(P < 0.05),
whereas
A. actinomyc
etemcomitan
s was
associated
with
periodontitis
in diabetic
patients
(P < 0.05).
checkerboard
immunoblotti
ng to assess
serum IgG
levels to 19
41

Edentulous
individuals
showed
lower
antibody

Demographic
,
behavioural,
and oral- and
general

IgG
responses
to
periodontal
bacteria in a
nationally
representati
ve sample
of US
adults. J
Clin
Periodontol
2010; 37:
685–696
Crosssectional
study.

multiple
periodontal
bacteria,
including
established/
putative
pathogens
and healthrelated
species, by
selected
demographi
c,
behavioural,
and oraland general
healthrelated
characteristi
cs.

from
the
third
Nationa
l Health
and
Nutritio
n
Examin
ation
Survey
(NHAN
ES III)
were
used,
includin
g 1588
edentul
ous
individ
uals.

periodontal
species
two-sided ttests
(p<0.05)
Multivariable
logistic
regression
modelling
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responses
than dentate
participants,
notably for
titres to ‘‘red
complex’’
species and A
actinomycete
mcomitans.
Elevated P
gingivalis
antibody IgG
titers was
significantly
different in
diabetes
including
type 1 or
type 2 than
having no
diabetes

healthrelated
characteristic
s were strong
determinants
of systemic
antibody
responses to
periodontal
bacteria in a
nationally
representativ
e sample of
US adults.
Diabetes as
an exact
diagnosis on
the type of
diabetes was
not available
in the present
analysis

Table2.2. Covariates from different data sources of NHANES III
Household
Adult
Interview
Questionnaires
data file
Age,
Sex,
Race/ethnicity
incomepoverty ratio,
education,
smoking,
Physical
activity,
self-reported
diabetes,
hypertension
and frequency
of dental visits

NHANES III
Examination
Data File

laboratory
NHANES III Antibodies Dietary
examination to Periodontal Pathogens recall and
data file
(SPSDEPPX)
vitamin
supplement
dataset
BMI,
Plasma
Aggregatibacter
total fibers
Waist
HbA1c%,
actinomycetemcomitans intake,
circumference, Plasma
mix (ATCC strains
Protein
Blood
Blood
#43718, #29523 and
intake,
pressure,
glucose,
#33384);
Carbohydrate
number of
Serum TriPorphyromonas
Intake,
missing teeth, glycerides,
gingivalis mix (ATCC
Fat intake
Clinical
Low
#33277 and #53978);
attachment
Density
Tannerella forsythia
loss (CAL),
Lipoprotein, ATCC#43037;
Pocket depth
High
Treponema denticola
(PD)
Density
OMGS#3271;
Lipoprotein, Campylobacter rectus
Systolic
ATCC#33238;
Blood
Eubacterium nodatum
Pressure,
ATCC#33099;
Diastolic
Prevotella intermedia
Blood
ATCC#25611;
Pressure
Prevotella nigrescens
ATCC#33563;
Prevotella
melaninogenica
ATCC#25845;
Fusobacterium
nucleatum
ATCC#10953;
Micromonas micros
ATCC #33270;
Selenomonas noxia
ATCC#43541;
Eikenella corrodens
ATCC#23834;
Capnocytophaga
ochracea ATCC#33624;
Streptococcus
intermedius
ATCC#27335;
Streptococcus oralis
ATCC#35037;
43

Streptococcus mutans
ATCC#25175;
Veillonella parvula
ATCC#10790; and
Actinomyces naeslundii
ATCC#49340
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Figure 2.1: Model for bidirectional relationship between periodontal infection and
diabetes, contributing to insulin resistance. (Ozmeric, 2004; Preshaw et al., 2012; Santos
Tunes, Foss-Freitas, & Nogueira-Filho Gda, 2010) (Santos Tunes, Foss-Freitas, and
Nogueira-Filho Gda 2010, Ozmeric 2004, Preshaw et al. 2012) (Santos Tunes, FossFreitas, and Nogueira-Filho Gda 2010, Ozmeric 2004, Preshaw et al. 2012) (14, 35, 68)
(14, 35, 68) (14, 35, 68) (Santos Tunes, Foss-Freitas, and Nogueira-Filho Gda 2010,
Ozmeric 2004, Preshaw et al. 2012) MMP: Matrix metalloproteinase, IL: Interleukin,
TGF-β: Transforming growth factor β, TNF-α: Tumor necrosis factor α, PGE2:
Prostaglandin E2, PMN: Poly morphonuclear leucocyte, AGE: Advanced glycation end
products, RAGE: Receptor for AGE
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Figure 2.2: Serum Immunoglobulin (IgG) to 19 periodontal bacteria species and their
respective phyla identified by Checkerboard hybridization in NHANES III study.
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ABSTRACT
Aim: To investigate the association between antibodies against oral microorganisms and
hyperglycemia in a nationally representative sample.
Methods: Participants in the NHANES III (1988-1994), aged ≥40 years, who provided
blood samples that were assessed for serum IgG titers against 19 periodontal bacteria (n =
8153) were included. Antibody titer z-scores were used to get four clusters (“OrangeRed”, “Red-Green”, “Orange-Blue” and “Yellow-Orange”) using cluster analysis.
Logistic regression weighted for complex survey design was used to analyze the
relationship between the clusters and hyperglycemia.
Results: The Orange-Red cluster score, that included P. gingivalis and Prevotella sps,
was positively associated with diabetes [OR 1.08 (1.03-1.13)] while Red-Green score
(which included A. actinomycetemcomitans mix, S. noxia, E. corrodens, V. parvula, T.
forsythia, T. denticola, C. rectus) was inversely related to diabetes [OR 0.96 (0.912 0.999)] in multivariable analyses. The Orange-Blue cluster (A. naeslundii and E.
nodatum) was inversely associated with diabetes and pre-diabetes but the relations were
attenuated after adjustment. The Yellow-Orange cluster, that included predominantly
Streptococcus sps, was not associated with hyperglycemia.
Conclusion: Clusters of serum IgG antibodies against periodontal bacteria are both
positively and negatively associated with diabetes. The relation between periodontal
bacteria and hyperglycemia is complex and deserves further study.
Key words: Type 2 diabetes; pre-diabetes; periodontal bacteria; serum IgG antibody;
NHANES III
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Introduction
Periodontitis is associated with diabetes and its related outcomes in observational
studies (Borgnakke et al. 2013). In prospective studies, periodontitis predicted the
development of type 2 diabetes (Demmer, Jacobs, and Desvarieux 2008), and type 2
diabetes mellitus at baseline predicted increased risk of incident self -reported
periodontitis and tooth loss (Jimenez et al. 2012), suggesting that the relation between
diabetes and periodontal diseases is bi-directional. However, the question whether
periodontal treatment improves glycemic control in individuals with diabetes remains
unanswered with randomized controlled trials (RCT) reporting discrepant results.
Engebretson et al reported no effect of periodontal treatment on glycemic control
(Engebretson et al. 2013), but Sun et al found that periodontal treatment improved
glycemic control, lipid profile, inflammatory cytokines among individuals with type 2
diabetes, and a systematic review of all RCTs found periodontal treatment to have a net
benefit (Engebretson and Kocher 2013, Sun et al. 2011). A possible drawback of these
studies was that none evaluated immunological changes evoked by periodontal pathogens
(Holmlund et al. 2011), which may explain the poorly understood mechanism linking
periodontal disease with glycemic control (Lalla and Papapanou 2011).
The periodontal environment harbors more than 700 different species of
periodontal microbiota (Socransky and Haffajee 2002, 2005) making it a potentially
important site for host microbe interaction (Rams, Listgarten, and Slots 2006). Several
periodontal bacteria are capable of invading the gingival tissues and initiating robust
serum antibody responses that are capable of interfering with host defense mechanisms
and stimulating local and systemic inflammations (Kinane and Lappin 2001). Recent
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studies (Teles et al. 2012, Socransky et al. 2013, Socransky and Haffajee 2005, 2002)
showed that periodontitis is associated with higher prevalence of Porphyromonas
gingivalis, Tannerella forsythia, Treponema denticola, Actinobacillus
actinomycetemcomitans, Prevotella sps.; whereas Actinomyces groups are predominantly
associated with healthy periodontal status. Furthermore, Dye et al (2009) (Dye et al.
2009) in a large nationally representative US population study from the third National
Health and Nutritional Examination survey (NHANES III) found that elevated serum
immunoglobulin (IgG) titers against P. gingivalis are associated with periodontitis while
elevated IgG titers against against Eubacterium nodatum are associated with healthy
periodontal status. There is growing evidence that the relationship between periodontal
disease and systemic diseases is affected by the profile of periodontal bacteria. For
instance, Desvarieux et al., in cross-sectional (Desvarieux et al. 2005) and longitudinal
(Desvarieux et al. 2013) studies reported that the etiologic group of periodontal bacteria
which included P. gingivalis, A. actinomycetemcomitans, T. forsythia and T. denticola
was associated with increased carotid intima media thickness, while the group that
included V. parvula and A. naeslundii was related with less carotid intima media
thickness. The humoral response of elevated P. gingivalis and, A.
actinomycetemcomitans titers has been linked to cardiovascular outcomes (Pussinen,
Alfthan, et al. 2007, Pussinen, Alfthan, Tuomilehto, et al. 2004, Pussinen et al. 2003,
Pussinen et al. 2005, Pussinen, Paju, et al. 2007).
A recent study (Le Chatelier et al. 2013) that linked selected gut microbiota with
adverse metabolic control markers reinforced our thinking about the possible role of
periodontal microbiota in hyperglycemia. The altered bacterial composition during
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periodontitis in reference to diabetes is well studied (Lalla et al. 2006, Li et al. 2013,
Field et al. 2012, Zhou et al. 2013) but the host response role in hyperglycemia is
understudied (Vlachojannis et al. 2010, Takahashi et al. 2001). In this study, our main
aim was to characterize the extent to which serological markers against oral
microorganisms were associated with diabetes and pre-diabetes. We hypothesized that
selected oral microorganisms would be positively, while others inversely associated with
hyperglycemia, based on what is known about the relation between the periodontal
biofilm clusters and health and disease (Socransky and Haffajee 2005, 2002, Desvarieux
et al. 2013), This is a small, but important, first step in our understanding of this question,
and sets the stage for further studies aimed at better understanding of mechanisms. If it is
discovered that oral micro-organism affect metabolic parameters, it may be possible to
impact metabolic parameters by altering the microbial profile.
Materials and Methods
Study Population
The NHANES III used a multi-stage, probability cluster sampling design to
provide nationally representative data on a variety of health risks and behaviors,
including both self-reported and objective estimates of diabetes and clinical and antibody
information related to periodontal disease. We included participants of the NHANES III
1988-1994 survey, aged 40 years or above who had complete information on serum IgG
antibodies titers against periodontal bacteria (Ezzati et al. 1992). Serum antibody titers
were assessed on stored blood samples and released for the first time in 2008.
We linked the following datasets from NHANES III public release data files:
NHANES III Household Adult Data File, NHANES III Examination Data File,
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NHANES III Laboratory Data File, NHANES III Dietary Recall Data Files, and
Antibodies to Periodontal Pathogens using a unique de-identified respondent
identification number provided to each participant. All data for this report are available
at: http://www.cdc.gov/nchs/nhanes/nh3data.htm
Out of 33,994 individuals in the NHANES III sample in the six year period
(1988-1994) 14,464 were aged 40 years or older, of which 11,448 were interviewed,
9379 were examined and 8153 provided sera that were analyzed for IgG titers against 19
periodontal bacteria (Vlachojannis et al. 2010). Of the eligible 8153 samples, we
excluded individuals who reported taking insulin or who had gestational diabetes leaving
7848 participants in the final sample for analysis.
IgG assay for periodontal bacteria
All available sera from NHANES III participants (1988-1994) 40+ years were
tested for the presence and level of IgG antibodies against a broad panel of periodontal
bacteria. The following 19 bacterial strains were used to prepare whole cell antigenic
extracts by checkerboard immunoassay: Aggregatibacter actinomycetemcomitans (ATCC
strains #43718, #29523 and #33384); Porphyromonas gingivalis (ATCC #33277 and
#53978); Tannerella forsythia (ATCC#43037); Treponema denticola (OMGS#3271);
Campylobacter rectus (ATCC#33238); Eubacterium nodatum (ATCC#33099);
Prevotella intermedia (ATCC#25611); Prevotella nigrescens (ATCC#33563); Prevotella
melaninogenica (ATCC#25845); Fusobacterium nucleatum (ATCC#10953);
Micromonas micros (ATCC #33270); Selenomonas noxia (ATCC#43541); Eikenella
corrodens (ATCC#23834); Capnocytophaga ochracea (ATCC#33624); Streptococcus
intermedius (ATCC#27335); Streptococcus oralis (ATCC#35037); Streptococcus mutans
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(ATCC#25175); Veillonella parvula (ATCC#10790); and Actinomyces naeslundii
(ATCC#49340).. The laboratory tests were performed at Columbia University College of
Dental Medicine, using the ‘‘checkerboard’’ immunoassay technique measured in
gravimetric units (Papapanou et al. 2000)(31)(Papapanou et al. 2000)(Papapanou et al.
2000). The detailed procedure of assessing IgG by checkerboard immunoassay is
described in NHANES III documentation:
ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/nhanes/nhanes3/30a/spsdeppx.pdf
Cluster Formation and Naming the Clusters
For each of 19 bacterial species, serum IgG antibody titer values were natural log
transformed and then standardized by dividing these values by the log-transformed
population standard deviation (Desvarieux et al. 2005). Standardized z-scores of serum
IgG of diabetes and pre-diabetes subgroups were used in cluster analysis to derive four
mutually distinct groups of periodontal bacteria. The standardized z-scores of IgG against
those periodontal bacteria in the respective clusters were summed to obtain cluster scores
for each group. These four cluster scores were the main exposure variables used in this
analysis.
We used the color scheme of microbial complexes given by Socransky and
Haffajee (Socransky and Haffajee 2005, 2002) to name these clusters. In that scheme,
organisms in the Red and Orange clusters are related to periodontal disease; organisms in
the Yellow and Purple clusters are associated with a healthy periodontal condition; the
Blue cluster includes Actinomyces species which is found in both periodontal disease and
in the healthy state; organisms in the Green cluster may be weakly related to periodontal
disease (Socransky et al. 1998, Socransky and Haffajee 2005, 2002). In naming the
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clusters, we put the dominant color of periodontal bacteria first. For example, if cluster
scores included 4 organisms of which 3 are from the Orange group and one from Red, we
named that cluster as Orange-Red. If there is a tie (i.e. same numbers of Red and Orange
cluster organisms then we started with Red). Further details are shown in figure 3.1. This
way we have four clusters named as “Orange-Red”, “Red-Green”, “Yellow- Orange” and
“Orange-Blue”.
Definition of Type 2 Diabetes and pre-diabetes
We defined pre-diabetes as having HbA1c 5.7 to <6.5% or fasting plasma glucose
(FPG) 100 to <126 mg/dl (5.6-6.9 mmol/L). Individuals with HbA1c ≥ 6.5% or FPG ≥
126 mg/dl [7 mmol/L] or those who self-reported diagnosed diabetes were classified as
having diabetes (Bullard et al. 2013).
Covariate Information
Demographic, lifestyle and anthropometric measures such as gender, age,
race/ethnicity, education, income-poverty ratio, smoking and alcohol drinking habits,
physical activity, fiber intake, frequency of regular dentist visits, waist circumference
(WC) and body mass index (BMI) are used as potential confounders. Race/ethnicity was
self-reported and was divided into four groups: non-Hispanic white, non-Hispanic black,
Mexican American and other. Income was grouped into three groups of the income-topoverty ratio (≤1.5, >1.5 to ≤3.0, and >3.0), education level into three groups ≤6 years; 7
to 12 years; and ≥13 years).
Smokers were defined into three groups (current, past and never smokers). A
never smoker was defined as an individuals who had smoked <100 cigarettes in his or her
lifetime. The alcohol drinkers were divided into three groups (current, past and never
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alcohol drinkers). Individuals who reported consuming less than 12 drinks in their lives
were “never drinkers”. Physical activity was divided into three groups based on
metabolic equivalents (METs) (active, ≥6; moderate, ≥4 and <6; and less active, <4).
People who had regular dental checkups were defined as those who had visited a
dental clinic at least once in the past year. WC to assess central obesity was measured
using a steel measuring tape to the nearest 0.1 cm at the high point of the iliac crest at
minimal respiration when the participant was in a standing position. Central adiposity
was said to be present if waist circumference was ≥101.6 cm for male subjects and ≥88.9
cm for female subjects. Missing teeth was categorized into four groups: none, 1-5, 6-10,
> 10 missing teeth (Choi et al. 2011). Dietary Fibers, carbohydrate, protein, fat, total
calories intake was assessed based on estimates from the 24-hour dietary recall.
Statistical Methods
SAS, version 9.3 (SAS Institute, Cary, NC) was used for data management and
statistical analyses. SAS survey procedures were used to take into account the complex
weighted sampling design and yielded unbiased parameter estimates and standard errors.
Sample weights, cluster, and strata variables provided by CDC were used. A statistically
significant α level was considered at 0.05.
Descriptive statistics were estimated using procedures for complex surveys in
SAS (proc surveymeans and proc surveyfreq). The distribution of socio-demographic,
lifestyle, anthropometric measures, and other potential risk factors across tertiles of each
of four cluster scores were estimated. The mean values of four clusters scores and z
scores of species –specific serum IgG were evaluated across the diabetes status.
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The multivariable survey logistic regression model was used. In the diabetes
status (diabetes, pre-diabetes and normal blood glucose), normal blood glucose group
was the reference in all analysis. The first model included the four clusters which were
regressed across the outcomes; in second model, we additionally adjusted for age
(continuous), sex, race and income-to-poverty ratio. In the third model, we adjusted
further for smoking and drinking alcohol and in the fourth model we included WC,
physical activity, BMI (continuous), and dentist visits. Finally, we then adjusted further
for missing teeth, dietary fibers, total energy, carbohydrate, protein and fat intake.
We repeated the same analysis by using the standardized z-scores of serum IgG
antibodies of 11 periodontal bacteria to obtain the 3 groups (etiologic, putative and health
related) as defined in a priori study by Desvarieux et al. (Desvarieux et al. 2005).
Results
The four mutually exclusive groups; “Orange-Red”, “Red-Green”, “YellowOrange” and “Orange-Blue” of periodontal bacteria antibodies obtained from cluster
analysis and their naming pattern are shown in Flow chart 1. In our study population of
7848 individuals, 9.6% had diabetes, 36.6% pre-diabetes, and 69.7% normal blood
glucose. The distribution of profile characteristics across the diabetes status are shown in
Table 3.1.There were higher numbers of Non-Hispanic Whites, females, high school
graduates, never smokers or past smokers but current or former alcohol drinkers,
overweight, with sedentary lifestyle and those who didn’t visit dentist at least once a year.
The general characteristics of study population by tertiles of cluster scores (sum of
standardized z- scores in periodontal bacteria antibodies in each respective cluster) are
shown in Table 3.2. There were a higher proportion of individuals with diabetes in the
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top versus bottom tertiles (11.2 vs 8.1) in Orange-Red cluster (which included P.
gingivalis and prevotella species), however the opposite trend (8.6 vs 11.1) was observed
for Orange-Blue (which included A. naeslundii and E. nodatum) and no such difference
was seen in other clusters and pre-diabetes also showed similar pattern. Whereas
distribution of participants with normal blood glucose showed an opposite pattern of
Orange-Red (56.1 vs 50.3) and Orange-Blue clusters (49.0 vs 56.4) when compared in
top vs bottom tertiles (Table 3.2). Age of the participants was similar across tertiles of all
clusters (on average 57years) but Orange-Blue had a higher proportion of older
participants compared to other clusters. BMI and fiber intake were relatively higher in top
tertiles across all four clusters (Table 3.2).
The mean z-scores of species specific serum IgG against 19 bacteria and their
respective four clusters are shown in Table 3.3. Significantly higher trend of z-scores of
Orange-Red were seen in diabetes compared to pre-diabetes and normal blood glucose
while decreasing trend of Orange-Blue clusters scores were observed in diabetes groups.
In this study, we found a one unit higher- Orange-Red cluster score was
associated with 11% (p value <0.0001) higher odds of type 2 diabetes when other clusters
scores were held constant. With further full adjustment for age, sex, race and income-topoverty ratio, cigarette smoking, alcohol drinking, physical activity, BMI, WC, dentist
visit, missing teeth, and different nutrients intake, the odds attenuated to 8% (p value
<0.05) (Table 3.4). With pre-diabetes, there was a 3% increased odds but after adjusting
for confounders, the association was not statistically significant. In Orange-Blue cluster
score, one unit increase was associated with 11% (p=<0.001) lowering odds of diabetes
and 7% (<0.05) lower odds of pre-diabetes holding all other clusters constant. Overall,
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there was an inverse but insignificant association between this cluster score and diabetes
and pre-diabetes after adjusting for all the measured confounders evaluated. Similarly, a
unit increase in Red-Green cluster score (which included A. actinomycetemcomitans mix,
S. noxia, E. corrodens, V. parvula, T. forsythia, T. denticola, C. rectus) showed an
inverse relation ) with diabetes but positive association with pre-diabetes, however
statistically not significant. Yellow Orange cluster score (which included S. intermedius,
S. oralis, S. mutans, F. nucleatum, M. micros, C. ochracea) showed no association with
pre-diabetes and diabetes (Table 3.4). (In a sensitivity analysis comparing dentate
(n=5458) and edentulous participants (n=2390) Orange-Red scores significantly
increased the odds of having diabetes by 15% [OR=1.15 (1.046-1.263) in edentulous
participants whereas Orange-Blue scores decreased the odds by 8% [OR=0.083 (0.800974) in dentate participants after adjusting for all confounders in the full model.
The relation between periodontal bacteria antibodies grouped in etiologic,
putative and health related categories (Desvarieux et al. 2005) with diabetes and prediabetes were described in Table 3.5. A one unit increase in etiologic group (which
included P. gingivalis, A. actinomycetemcomitans, T. denticola, T. forsythia) score was
associated with 7% and 4% (both p values <0.05) higher odds of diabetes and prediabetes respectively. The health related group that comprised V. parvula and A.
naeslundii was inversely related to diabetes (13% lower odds, p value <0.001) and prediabetes (7% lower odds, p value <0.05). After adjustment for measured confounders, the
etiologic and health related group association remained insignificant for both diabetes
and pre-diabetes. The putative group that included E. corrodens, C. rectus, F. nucleatum,
M. micros, and P. intermedia was not associated with diabetes and pre-diabetes.
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Discussion
The association between clusters of serum IgG antibodies against periodontal
bacteria and hyperglycemia varied qualitatively in a large, representative sample of US
adults. Increased Orange-Red cluster titers were associated with 8% higher odds of
diabetes while increased Red-Green cluster titers were associated with 4% lower odds
after adjustment for potential confounders. The Orange-Red cluster included
periodontopathic bacteria that are linked to local inflammatory response, hard and soft
tissue breakdown leading to clinical signs of local periodontitis, and systemic
inflammation.
There is a strong biological rationale behind using cluster analysis in this study.
Since periodontal bacteria coexist naturally in a biofilm, it is therefore to isolate the
potential effects of particular pathogens; moreover, studies evaluating the effects of
individual organisms are prone to type 1 error(Wang et al. 2007). To overcome this
limitation some investigators have grouped the periodontal organisms together either
using empirical or theoretical approaches (Socransky and Haffajee 2002, Desvarieux et
al. 2005). Specific clusters of periodontal bacteria profiles for type 2 diabetes have not
been reported in the literatures. In the current study, we used both empirical as well as
theoretical approaches to group antibodies against oral pathogens among individuals with
hyperglycemia and measured the extent of association of these bacteria with diabetes and
pre-diabetes. We did this because we were interested in evaluating the relative (rather
than absolute) contributions of the titers to the overall score.
The immunological role of some periodontal bacteria such as P. ginigvalis, and A.
actinomycetemcomitans in relation to periodontitis and other systemic disease has been
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reported in recent studies. Elevated serum anti- P. gingivalis antibody has been associated
with ishemic stroke (Pussinen, Alfthan, Rissanen, et al. 2004), myocardial infarction
(Holmlund et al. 2011, Pussinen, Alfthan, Tuomilehto, et al. 2004) and coronary heart
disease (Pussinen et al. 2003) but A. actinomycetemcomitans showed inconsistent
relationships in different populations (Mantyla et al. 2013, Hosomi et al. 2012, Pussinen
et al. 2005).
There are few studies evaluating serum antibody titers against periodontal bacteria
and diabetes. Ebersole et al (Ebersole et al. 2008) compared serum antibody levels of P
gingivalis, A actinomycetemcomitans,T. denticola, T. forsythia, C. rectus,F. nucleatum,
E. corrodens, and P.intermedia using standard enzyme-linked immunosorbent assay
methodology in type 2 diabetes and non-diabetes group. Antibodies against P gingivalis
were significantly elevated in the diabetes group while serum IgG responses to other
microbes were broadly similar between the two groups. However, these studies had small
sample sizes, differences in characteristics of the study populations, and methods of
detecting of periodontal microbiota, making it difficult to compare the findings. Another
study (Vlachojannis et al. 2010) included both type 1and type 2 diabetes cases found
elevated titers of P. gingivalis associated with diabetes.
In our study, the Orange-Red cluster scores and the etiologic group that included
P. gingivalis were positively associated with hyperglycemia (Table 3.4 and Table 3.5).
Interestingly, the cluster Red-Green that included antibodies against three organisms that
have been associated with periodontitis and systemic disease (Desvarieux et al. 2005)
was inversely related with diabetes in this study (Table 3.4). This may be because this
cluster also included the purple complex organisms, V. parvula, which has been linked to
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healthy periodontal status (Desvarieux et al. 2005), and could have shadowed the effect
of the Red-cluster organisms. There are no specific similar studies related to diabetes to
compare our findings but a study evaluating serum IgG antibodies against 12 periodontal
pathogens among Japanese children with type-1 diabetes mellitus found significantly
higher antibody titers to P. gingivalis, P intermedia and T denticola compared to other
periodontal bacteria (Takahashi et al. 2001). In a separate recent study (Hosomi et al.
2012), serum IgG antibody against P. gingivalis was significantly associated with atrial
fibrillation, and antibody against P. intermedia was associated with carotid artery
atherosclerosis and atherothrombotic stroke whereas no such association was seen with
anti- A. actinomycetemcomitans serum antibody. Our findings support the hypothesis that
P. gingivalis may have a major role in systemic conditions including diabetes compared
to other periodontal pathogens (Jeong et al. 2012).
The Orange-Blue cluster scores that included A. naeslundii and E. Nodatum
showed an inverse relation to diabetes and pre-diabetes in the crude analysis but that was
attenuated after adjustment [diabetes: OR 0.935 (0.869-1.007), pre-diabetes OR: 0.987
(0.944-1.032) (Table 3.4). Several studies have shown that the higher counts of A.
naeslundii are associated with periodontal healthy status (Socransky and Haffajee 2002,
Desvarieux et al. 2005, Socransky and Haffajee 2005, Darveau 2010, Papapanou et al.
2000) but a case-control study (Haffajee, Teles, and Socransky 2006) reported higher
level of E. nodatum to be associated with periodontitis and another (Lalla et al. 2006)
reported an association with type 1 diabetes. The health related group that included A.
naeslundii and V. parvula was inversely related to pre-diabetes and diabetes (Table 3.4)
which supports the evidence that long term predominance of A. naeslundii in the
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periodontal area may be related to healthy clinical outcomes and may play a protective
role in systemic conditions.
Yellow-Orange cluster scores which included health-related bacteria,
Streptococcus species and C. ochracea showed no distinct association with either of the
outcomes. This might be due to the presence of serum IgG of other periodontal bacteria
such as F. nucleatum, M. micros in this cluster scores which had the putative role
(Haffajee, Teles, and Socransky 2006, Shin et al. 2013).
Our study has some drawbacks. As this was a cross-sectional study, we could not
verify the temporal sequence of the associations. As is the case with all observational
studies unmeasured confounding could potentially impact the results. However, we
adjusted for a number of known potential confounders in our analyses. We did not adjust
for clinical measures of periodontal disease (such as clinical attachment loss or probing
depth) because these are on the causal pathway (periodontal microorganisms cause
attachment loss and periodontal pockets), and adjusting for them would likely introduce
bias (Cole and Hernan 2002). This dataset included information from 1988-1994. Even
though the prevalence of periodontal disease, diabetes and other covariates such as
smoking have changed over this time, this would not impact our results because change
in prevalence does not impact the relation between the exposure and outcome (Szklo and
Nieto 2007). In this dataset, there are information on only 19 periodontal bacteria, hence
a new sophisticated study that combines the immunological, microbiological and clinical
information of periodontal disease are needed to provide further insights in systemic
association and further study of undisputed hypothesis that oral health could be important
source of chronic inflammation.
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The study also had some strength. The CDC conducted assays for an expanded
panel of antibodies against periodontal microorganisms on stored blood samples from the
NHANES III and released the results in 2008. This was timely, because there is renewed
interest in studying the relation periodontal microorganisms and the microbiome in
relation to systemic outcomes. The NHANES III dataset has good quality information for
periodontal disease, serum IgG antibodies against 19 different periodontal bacteria,
diabetes, and other covariates of interest in a large, representative number of US adults.
Serum IgG against A. actinomycetemcomitans and P. gingivalis are stable over at least 15
years (Lakio et al. 2009), and represent a measure of cumulative lifetime infection of
periodontal disease and host response towards it. For this reason we included edentulous
individuals in the main analyses, however, the results did not change materially when
missing were adjusted (Table 3.4 and Table 3.5). These data have not been reported on
extensively and hence provide new information.
The association between antibodies against oral microorganisms and
hyperglycemia moderately varied by the type of periodontal organisms that are involved
in a large, representative sample of US adults. Monitoring the type of periodontal bacteria
in plaque may be important in individuals with diabetes and pre-diabetes.
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Table 3.1− Profile characteristics of study population NHANES III (1988-1994)
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Age, years, mean (se)
Sex: %
Male
Female
Race/ Ethnicity %
Non-Hispanic Whites
Non –Hispanic Blacks
Mexican American
Others
Education %
≤ 6 years
7 – 12 years
≥ 13 years
Income to poverty ratio %
Lower (≤1.5)
Middle (≤3.0)
Higher (>3.0)
Smoking %
Current
Past
Never
Alcohol intake %
Current
Past
Never
Physical activity %
Sedentary

Normal(n=3424)
53.85 (0.3)

Pre-diabetes(n=3334)
59.5(0.6)

Diabetes(n=1090)
61.7(0.6)

42.7
57.3

50.2
49.8

46.8
53.2

85.3
6.1
2.6
5.9

76.9
11.3
3.9
7.9

71.6
14.6
6.0
7.7

4.7
50.4
44.9

8.5
57.6
33.9

12.3
62.2
25.4

15.0
28.6
56.4

22.0
30.5
47.4

30.2
31.5
38.3

41.6
41.7
16.7

35.1
46.4
18.5

37.2
47.3
15.5

13.9
34.0
52.0

15.3
42.2
42.5

20.0
48.9
31.1

54.8

49.3

45.6

Moderately active
Vigorously active
Missing
Missing Teeth, %
0
1-5
6-10
>10
Annual visits to dentist %
Yes
No
Waist circumference %
Normal
Elevated
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Dietary Fibers, g/day, mean (se)
Total Carbohydrate, g/day,
mean (se)
Proteins, g/day, mean (se)
Total fats, g/day,mean (se)
BMI, kg/m2, mean (se)
Orange-Red score, mean (se)
Red-Green score, mean (se)
Yellow-Orange score, mean (se)
Orange-Blue score, mean (se)

12.3
8.0
24.9

13.4
7.4
29.8

11.1
6.7
36.6

53.1
37.1
7.7
2.1

51.7
34.7
9.3
4.3

50.5
29.7
12.1
7.8

59.1
40.9

43.9
56.1

38.4
61.6

60.0

45.2
54.8

23.8
76.2

40.0
17.2(0.3)

16.4(0.3)

16.2(0.5)

250.5(4.1)
76.6(1.0)
77.0(1.3)
26.4(0.1)
-0.5 (0.1)
-0.1 (0.3)
-0.01(0.2)
0.2 (0.1)

243.9(4.1)
77.8(1.3)
75.7(1.6)
27.8(0.2)
-0.3(0.1)
0.02(0.3)
0.004(0.2)
0.07(0.1)

222.7(5.1)
75.0(2.2)
70.4(2.8)
30.1(0.3)
0.1(0.2)
-0.2(0.5)
0.06(0.3)
-0.04(0.1)

Table 3.2− Distribution of general characteristic of study population (n=7848) in the top vs bottom tertiles of four different clusters
scores
Variables

a

n

Orange-Red

Red-Green

Yellow-Orange

Orange-Blue

Tertile1

Tertile3

Tertile1

Tertile3

Tertile1

Tertile3

Tertile1

Tertile3

Sex (%)
Male

3677

40.1

50.3

41.3

49.8

42.9

47.0

45.9

46.7

Female

4171

59.9

49.7

58.7

50.2

57.1

52.4

54.1

53.3

≤ 6 years

1403

5.5

9.2

5.7

7.3

7.0

7.1

7.9

5.1

7 – 12 years

4344

57.2

52.1

58.5

50.5

58.6

52.0

58.7

49.3

≥ 13 years

2046

37.3

38.7

35.8

42.3

34.4

40.9

33.4

45.6

Lower (≤1.5)

2387

18.5

20.6

19.3

17.7

22.4

18.4

22.8

15.0

Middle (≤3.0)

2214

28.8

28.8

30.6

30.4

28.8

30.8

33.0

27.2

High (>3.0)

2496

52.7

50.6

50.1

51.9

48.8

50.8

44.1

57.8

Non-Hispanic Whites

4012

87.6

71.9

85.8

76.2

84.0

76.7

80.4

82.6

Non-Hispanic Blacks

1817

5.6

13.4

6.8

10.8

7.4

11.2

9.8

8.3

Mexican Americans

1699

2.2

4.9

2.8

4.1

2.9

3.8

3.1

3.6

Education (%)

86

b

Income to poverty ratio

(%)

Race/ethnicity (%)

Other

320

4.6

9.8

4.6

8.9

5.7

8.3

6.7

5.5

Never smoker

3562

39.5

46.3

37.5

45.9

38.7

45.7

38.6

46.5

Past smoker

2521

33.2

35.5

34.2

36.7

33.3

35.3

32.7

35.4

Current Smoker

1765

27.3

18.2

28.3

17.4

28.0

19.0

28.7

18.1

Never drinker

1480

15.6

15.7

14.7

16.1

15.2

16.2

17.2

13.6

Past drinker

3185

38.3

37.4

38.5

38.9

38.7

37.6

39.6

38.3

Current drinker

3031

46.1

46.9

46.7

45.0

46.1

46.2

43.2

48.1

Yes

3010

51.7

52.0

49.4

52.2

48.1

54.6

47.9

55.3

No

4588

48.2

8.1

50.6

47.8

51.9

45.4

52.0

44.7

Sedentary

3550

53.6

51.7

54.4

50.3

51.6

50.5

51.3

54.5

Active

927

12.3

11.4

11.1

12.3

12.0

11.8

12.1

12.4

Vigorously active

500

6.8

7.8

7.2

7.8

7.6

8.2

6.8

8.1

Normal

3602

52.1

49.4

50.5

49.4

51.9

51.2

50.9

52.0

Elevated

3904

47.9

50.6

49.5

50.6

48.2

48.8

49.1

48.0

Cigarette Smoker (%)

Alcohol (%)

Dentist visit once in year
87

(%)

Physical Activity (%)

c

Central Obesity (%)

Diabetes Status (%)
Diabetes

1090

8.1

11.2

9.2

9.8

10.4

10.5

11.1

8.6

Pre-diabetes

3334

35.9

38.5

37.1

37.6

38.1

36.2

39.9

35.1

3424

56.1

50.3

53.7

52.6

51.5

53.3

49.0

56.4

Normal

Mean ± SD (n)

88

AGE (years)

56.9±0.5

56.6±0.6

56.8±0.5

56.5±0.6

57.8±0.6

56.2±0.6

58.4±0.6

57.1±0.1

BMI (kg/m2)

26.9±0.2

27.8±0.2

27.0.9±0.
2

27.7±0.2

26.9±0.2

27.5±0.2

26.9±0.2

27.3±0.2

Fiber Intake (g/day)

16.1±0.3

17.0±0.3

15.8±0.3

17.3±0.3

16.0±0.3

16.9±0.2

16.3±0.3

16.5±0.3

HbA1c (%)

5.5±0.0

5.6±0.0

5.5±0.03

5.5±0.0

5.6±0.0

5.6±0.0

5.6±0.0

5.6±0.0

Fasting Plasma Glucose
(mg/dl)

99.8±0.6

103.5±1.
1

101.7±0.8

101.8±0.
9

102.7±0.
9

102.1±1.
1

103.9±1.
1

101.3±0.
9

a

Totals may be different due to missing data
Income-to-poverty ratio: (midpoint family income)/(poverty threshold values based on calendar years and inflation)
c
Central adiposity present if waist for male subjects ≥101.6 cm and for female subjects ≥88.9 cm
b

Table 3.3− Mean z-score values of four cluster scores and the species-specific IgG antibody titers across diabetes status
Clusters/Periodontal Bacteria

Normal blood glucose
(N= 3424)
Clusters z-scores mean (SEM)

Pre-diabetes
(N= 3334)

Diabetes
(N= 1090)

P-trend

Orange-Red

-0.45 (0.1)

-0.26 (0.1)

0.11 (0.2)

0.0008

Red-Green

-0.11 (0.4)

0.02 (0.3)

-0.15 (0.5)

0.7753

Yellow- Orange

-0.01 (0.2)

0.004 (0.2)

0.06 (0.3)

0.7443

Orange-Blue

0.24 (0.1)

0.08 (0.1)

-0.04 (0.1)

0.0009

89

Species specific z scores mean (SEM)
Porphyromonas gingivalis

-0.22 (0.03)

-0.12 (0.03)

-0.05 (0.05)

0.0014

Prevotella intermedia

-0.12 (0.02)

-0.09 (0.02)

-0.02 (0.04)

0.0248

Prevotella nigrescens

-0.06 (0.03)

-0.03 (0.03)

0.06 (0.04)

0.0338

Prevotella melaninogenica

-0.05 (0.03)

-0.02 (0.03)

0.11 (0.1)

0.0051

Tannerella forsythia

0.01 (0.1)

0.01 (0.1)

0.03 (0.1)

0.6760

Veillonella parvula

-0.01 (0.04)

0.01 (0.04)

0.003 (0.1)

0.5443

90

Selenomonas noxia

-0.004 (0.1)

0.03 (0.04)

-0.02 (0.1)

0.7147

Campylobacter rectus

-0.08 (0.1)

-0.05 (0.04)

-0.01 (0.1)

0.1231

Treponema denticola

0.02 (0.1)

0.001 (0.04)

-0.02 (0.1)

0.4837

Aggregatibacter actinomycetemcomitans

-0.04 (0.1)

0.004 (0.1)

-0.04 (0.1)

0.4167

Eikenella corrodens

-0.01 (0.1)

0.01 (0.1)

-0.10 (0.1)

0.3792

Fusobacterium nucleatum

-0.02 (0.03)

-0.03 (0.03)

0.03 (0.03)

0.6345

Streptococcus intermedius

-0.03 (0.04)

0.01 (0.1)

0.07 (0.1)

0.0084

Streptococcus oralis

-0.02 (0.04)

-0.01 (0.1)

-0.01 (0.1)

0.8761

Streptococcus mutans

-0.02 (0.04)

-0.01 (0.04)

0.01 (0.1)

0.6087

Micromonas micros

0.05 (0.03)

0.06 (0.03)

0.004 (0.1)

0.6065

Capnocytophaga ochracea

0.02 (0.03)

-0.02 (0.03)

-0.04 (0.1)

0.1589

Eubacterium nodatum

0.12 (0.04)

0.03 (0.04)

-0.02 (0.1)

0.0015

Actinomyces naeslundii

0.12 (0.03)

0.05 (0.03)

-0.02 (0.03)

0.0024

Table3.4−Odds Ratios (OR) & 95% CI for Type-2 diabetes and pre-diabetes in different clusters scores
Models
OR
(95%
CI)
Model1

Type 2 DIABETES
Orange-Red
Red-Green
0.979
1.111***
(1.067- 1.157) (0.943 - 1.017
)
1.074*
0.963
(1.026-1.124) (0.925-1.002)

YellowOrange

OrangeBlue

PRE-DIABETES
Orange-Red Red-Green

YellowOrange

OrangeBlue
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1.002
1.024
0.971
0.888**
1.035 *
0.927 *
(0.955(0.993 - 1.056 (0.936-1.008) (0.881(0.831(1.0021.051)
)
0.949)
1.069)
0.949)
Model2
1.026
0.962
1.014
1.011
0.988
0.975
(0.978(0.901(0.981(0.979-1.044) (0.951-1.027) (0.9321.078)
1.028)
1.047)
1.020)
*
*
Model3 1.080
1.033
0.956
1.015
1.014
0.983
0.983
0.957
(0.897 (0.980 (0.981- 1.047) (0.948 (0.939 (1.029-1.133) (0.919- 0.997) (0.9851.084)
1.019)
1.051)
1.024)
1.029)
Model4 1.082 *
1.049
0.929
1.022
1.005
0.993
0.987
0.955 *
(0.861(0.988(0.969 -1.043) (0.951-1.037) (0. 942 (1.032-1.134) (0.912 -0.999) (0.9931.109)
1.001)
1.058)
1.033)
*
*
Model5 1.079
0.956
1.048
0.935
1.023
1.005
0.993
0.987
(0.869(0.988(0.969 -1.043) (0.951-1.038) (0. 944 (1.031-1.130) (0.912 -1.001) (0.9921.108)
1.007)
1.059)
1.032)
Model1 with no adjustment for confounders; Model2 adjusted for age (continuous), sex, education, ethnicity, income-to-poverty;
Model3 adjusted further for smoking and drinking alcohol; Model4 further for physical activity, BMI (continuous), waist
circumference [WC],dentist visit and fibers intake. Model5 adjusted further for missing teeth, daily carbohydrate intake, protein
intake, fat intake, and total calories intake.
p-value <0.05, **p-value <0.001, *** p-value <0.0001
Orange-Red: P. melaninogenica, P. intermedia, P. nigrescens, P. gingivalis
Red-Green: T. forsythia, T. denticola, A. actinomycetemcomitans, E. corrodens, S. noxia, V. parvula, C. rectus
Yellow-Orange: S. intermedius, S. oralis, S. mutans, F. nucleatum, M. micros, C. ochracea
Orange-Blue: E. nodatum, A. naeslundii

Table 3.5− Odds Ratios & 95% CI for type-2 diabetes and pre-diabetes in different groups of z-scores titers (classified according to
Desvarieux et al., 2005)
Models
OR
(95% CI)

Type 2 DIABETES
Etiologic

Putative

PRE-DIABETES
Health

Etiologic

Putative

Health

1.003
1.001
1.067*
0.871**
1.041*
0.927*
(0.958- 1.050) (0.803-0.945)
(0.971- 1.031)
(1.003 - 1. 135)
(1.002 - 1.080)
(0.87-0.988)
Model2
1.047
0.991
0.947
1.037
0.989
0.968
(0.980-1.118)
(0.948-1.035)
(0.87-1.034)
(0.998-1.077)
(0.957-1.023)
(0.90-1.041)
*
Model3
1.044
0.995
0.945
0.986
0.974
1.040
(0.976 - 1.115)
(0.951-1.041)
(0.867-1.029)
(0.954-1.019)
(0.906-1.051)
(1.001 - 1.08)
*
Model4
1.024
1.014
0.949
0.986
0.980
1.044
(0.957 - 1.096)
(0.958-1.072)
(0.868-1.039)
(0.952-1.021)
(0.906-1.061)
(1.004 - 1. 086)
*
Model5
1.014
1.019
0.959
0.987
0.980
1.044
(0.948 - 1.084)
(0.963-1.079)
(0.880-1.045)
(0.954-1.022)
(0.908-1.058)
(1.004 - 1. 085)
Model1 with no adjustment for confounders; Model2 adjusted for age (continuous), sex, education, ethnicity; Model3 adjusted further
for smoking and drinking alcohol; Model4 further for physical activity, BMI (continuous), WC, dentist visit and fibers intake. Model5
adjusted further for missing teeth, daily carbohydrate intake, protein intake, fat intake, and total calories intake.
*
P-value <0.05, **P-value <0.001,
Etiologic: P. gingivalis , A. actinomycetemcomitans, T. forsythia, T. denticola
Putative: F. nucleatum, M. micros, C. rectus, P. intermedia, E. corrodens
Health : V. parvula, A. naeslundii
Model1

92

93
Figure 3.1: Composition of mutually exclusive four clusters formed with cluster analysis of z scores of 19 periodontal serum antibody
titers. Naming of clusters was done using predominant Socransky’s microbial color complexes as shown in parenthesis in the
respective cluster.
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Abstract:

Chronic periodontitis is a silent infectious disease that is prevalent worldwide in
adults and is associated with chronic diseases. Elevated serum IgG markers against
selected periodontal bacteria are associated with periodontal disease or health. The
interaction between the serological markers and clinical periodontal measures is
understudied in relation to systemic diseases. Our objective was to investigate the joint
association of clinical periodontal measures and serological markers in relation to
diabetes.
We evaluated the interaction in a cross-sectional study among adult participants
who were 40 years or older from nationally representative NHANES III (1988-1994)
survey. Serum IgG antibody titers against 19 periodontal bacteria from those participants
who had glycated hemoglobin ≥5.7 were grouped into four clusters and were named as
Orange-Red, Red-Green, Yellow-Orange and Orange-Blue according to Socransky &
Haffagee color complex scheme. Mean clinical attachment loss (CAL) and pocket depth
(PD) were divided into tertiles. we further defined the periodontal status as moderate to
severe or normal based on CAL and PD and the outcome was defined as having diabetes
or normal blood glucose level (n=2908). We performed survey logistic procedures in
SAS 9.3 to explore the role of clinical periodontal measures on the relations between
serological clusters and diabetes.
The inverse association between the Orange-blue cluster score (that included E.
nodatum and A. neslundii antibody titers) was stronger in the top versus bottom tertile of
mean periodontal pocket depth ORTertile 1= 1.07, 95% CI (0.89, 1.29), ORTertile 2= 0.84,
95% CI (0.72, 0.98) and ORTertile 3= 0.74, 95% CI (0.60, 0.91), p-value for
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interaction=0.07 after multivariable adjustment.
The relation between IgG antibody groups and diabetes were varied by tertiles of
periodontal pocket depth. This suggests that clinical parameters and antibody titers
against periodontal antibodies in combination can predict the hyperglycemic condition.

Introduction

Periodontal disease results from low grade chronic inflammation by multiple
indigenous organisms (Thomas et al. 2012) that leads to tissue destruction. Traditionally,
diagnostic parameters such as clinical attachment loss (CAL) and probing depths are used
in assessing the periodontal disease. Despite extensive research in the area of serological
makers of periodontal pathogens (Albandar et al. 2002, Dye et al. 2005, Dye et al. 2009,
Mustapha et al. 2007, Papapanou et al. 2004, Pussinen et al. 2011), these are not
commonly used in periodontal disease assessment. A possible reason may be that the
interpretation of elevated antibodies titers against specific periodontal bacteria is not
straightforward (Lockhart et al. 2012); high levels of antibodies may either indicate
effective host defense, or chronic failure to control the pathogen and be prognostic of
major periodontal tissue destruction (Albandar et al. 2002). Hence, both clinical measures
(CAL and Probing depth), and host defense measures (antibody titers against periodontal
pathogens), may provide important information about different aspects of the periodontal
disease process, particularly in relation to systemic disease (Mustapha et al. 2007).
Elevated serum immunoglobulin G (IgG) antibody titers against specific
periodontal bacteria e.g. Porphyromonas gingivalis , Prevotella sps are linked to
inflammatory diseases such periodontal pathogenesis, coronary heart disease, type 2
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diabetes, myocardial infraction and others (Ebersole et al. 2008, Mustapha et al. 2007,
Oppermann, Weidlich, and Musskopf 2012, Pussinen et al. 2007, Pussinen et al. 2004,
Pussinen et al. 2005, Albandar et al. 2002); elevated IgG titers against E. nodatum are
linked to periodontal health (Dye et al. 2009). In general there is a shift in periodontal
microbiota associated with systemic health states (Berezow and Darveau 2011). It is well
understood that elevated serum IgG antibody titers against specific periodontal bacteria
may reflect history of past infection by those bacteria (Lakio et al. 2009, Kinane and
Lappin 2001); however, there is very limited knowledge about the combined effect of
periodontal destruction status and elevated antibody titers on systemic disease activity.
We previously clustered serum IgG antibody titers against 19 periodontal bacteria
into four empirically derived clusters, and investigated their relation to hyperglycemia.
We found that measures of hyperglycemia were higher among individuals with high
antibody titers against certain oral microbes, and lower among others (unpublished
findings). In this present study, we used these four clusters of antibodies against
periodontal microorganisms and investigated if the presence of clinical periodontal
disease outcome assessed by CAL and PD modified their association with diabetes. This
finding will increase understanding of the potential combined effect of measures of
periodontal destruction and antibody titers against periodontal microorganisms in relation
to diabetes.
Materials and Methods:
Data Source and study population:
The periodontal serum IgG antibody titers analyzed for this cross-sectional study
were from adult participants who were 40 years or older who participated in the
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nationally representative NHANES III (1988-1994) survey. The NHANES III used a
multi-stage probability cluster sampling design to provide nationally representative data
on a variety of health risks and behaviors, including both self-reported and objective
estimates of diabetes and medical conditions, oral health data from dental examination,
and antibody information related to periodontal disease. The selection and sampling
methods are described elsewhere (Ezzati et al. 1992).
We included participants with complete information on serum IgG antibodies
against 19 oral bacteria (n=8153) and relevant socio-economic, anthropometric,
laboratory and nutritional data available. For this purpose, we linked the dataset with
information on antibodies against periodontal pathogens (SPSDEPPX) with the following
datasets from NHANES III public release data files: NHANES III Household Adult Data
File (Catalog Number 77560), NHANES III Examination Data File (Catalog Number
76200); NHANES III Laboratory Data File (Catalog Number 76300); NHANES III
Dietary Recall Data Files (Catalog Number 76700) using a unique de-identified
respondent identification number (SEQN NO) provided to each participants. All data for
this report are available at: http://www.cdc.gov/nchs/nhanes/nh3data.htm
IgG assay for periodontal bacteria
Most sampled persons giving blood samples in the mobile examination center
(MEC) provided additional blood sample that were stored at -700C for future laboratory
tests. 8153 persons had sera analysed for IgG antibodies to 19 oral bacterial species. The
following 19 bacterial strains were used to prepare whole cell antigenic extracts by
checkerboard immunoassay: Aggregatibacter actinomycetemcomitans (ATCC strains
#43718, #29523 and #33384); Porphyromonas gingivalis (ATCC #33277 and #53978);
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Tannerella forsythia (ATCC#43037); Treponema denticola (OMGS#3271);
Campylobacter rectus (ATCC#33238); Eubacterium nodatum (ATCC#33099); Prevotella
intermedia (ATCC#25611); Prevotella nigrescens (ATCC#33563); Prevotella
melaninogenica (ATCC#25845); Fusobacterium nucleatum (ATCC#10953); Parvimonas
micra (previously named Micromonas micros) (ATCC #33270); Selenomonas noxia
(ATCC#43541); Eikenella corrodens (ATCC#23834); Capnocytophaga ochracea
(ATCC#33624); Streptococcus intermedius (ATCC#27335); Streptococcus oralis
(ATCC#35037); Streptococcus mutans (ATCC#25175); Veillonella parvula
(ATCC#10790); and Actinomyces naeslundii (ATCC#49340). The laboratory tests were
performed by the Oral and Diagnostic Sciences Laboratory, Columbia University College
of Dental Medicine, using the ‘‘checkerboard’’ immunoassay technique measured in
gravimetric units and these laboratory reports were made available in 2008. The specific
laboratory method and quality control and monitoring for the measurement of serum IgG
titers are described in the documentation of NHANES III (National Center for Health
Statistics 2008). The detailed procedure of assessing IgG by checkerboard immunoassay
is described in NHANES III documentation:
ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/nhanes/nhanes3/30a/spsdeppx.pdf
Cluster Formation and Naming the Clusters
For each bacterial species, serum IgG antibody titer values were natural log
transformed and then standardized by dividing these values by the log-transformed
population standard deviation (Desvarieux et al. 2013, Desvarieux et al. 2005). We then
selected homogenous subpopulation of those individuals who have blood glucose greater
than HbA1c ≥ 5.7 (n=3049) and by using cluster analysis we derived four mutually
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distinct groups of periodontal bacteria. The specific bacteria that were grouped in each
cluster were shown in Flowchart1.The standardized z-scores of IgG against those
periodontal bacteria in the respective clusters were summed to obtain cluster scores for
each group. These four cluster scores were the main exposure variables used in this
analysis.
We named each cluster according to the dominant color scheme of microbial
complexes given by Socransky and Haffajee (Socransky and Haffajee 2005, 2002). For
instance, if a cluster had bacteria mixture of Red, Orange and other complexes, then the
cluster was named according to the predominant bacterial complex. We obtained four
clusters named as “Orange-Red”, “Red-Green”, “Yellow- Orange”, and “Orange-Blue”
as described in Figure 3.1.
Measurement of periodontal health
We assessed periodontal damage by PD and CAL. The detailed method is
described elsewhere (Choi et al. 2011). CAL of 1–2 mm is considered to be slight, 3–4
mm moderate, and ≥5 mm severe. Dental examiners trained on the NHANES protocol
examined all participants at mobile examination centers. Periodontal health assessment
was based on CAL and pocket depth measurements made at two sites (midbuccal and
mesiobuccal) on every tooth in each of two randomly chosen quadrants, one in maxilla
and the other in mandible as described in the NHANES procedures manuals. In total, 28
sites and 14 teeth per individual were measured if the subject had no history of tooth
removal excluding third molars (Choi et al. 2011).
We computed mean CAL and PD and grouped individuals into tertiles; the lowest
tertile having least periodontal damage as has been describe elsewhere (Choi et al. 2011).
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Definition of Diabetes
Individuals were defined as normal (n=2595) if HbA1c was <5.7% or fasting
plasma glucose (FPG) <100 mg/dl (<5.6 mmol/L). Individuals with HbA1c ≥ 6.5% or
FPG ≥ 126 mg/dl [7 mmol/L] or those who self-reported diagnosed diabetes were
classified as having diabetes (n=738) (Bullard et al. 2013).
Covariate Information
The covariates included demographic, lifestyle and anthropometric measures such
as gender, age, race/ethnicity, education, income-poverty ratio, smoking and alcohol
drinking habits, physical activity, fiber intake, frequency of regular dentist visits, waist
circumference (WC), body mass index (BMI) and diabetes. Race/ethnicity was selfreported and was divided into four groups: non-Hispanic white, non-Hispanic black,
Mexican American and others. Income was grouped into three groups of the income-topoverty ratio (≤1.5, >1.5 to ≤3.0, and >3.0), education level into three groups ≤6 years; 7
to 12 years; and ≥13 year. The number of missing teeth into four groups (0, 1–5, 6–10,
and ≥11).
Smokers were defined into three groups (current, past and never smokers). For
instance, if they said yes to the question “Do you smoke now” then they were defined as
current cigarettes smokers. If not, then based on the question “Have you smoked 100+
cigarettes in life”, we defined them as past smoker or not smoker. Alcohol drinkers were
divided into three groups (current, past and never alcohol drinkers). If individuals said
“No” to the question “Had at least 12 drinks in life” were “Never Drinkers”. Those who
said “yes” were asked next question “Had at least 12 drinks in last 12 months”, if they
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said yes then were defined as “Current Drinkers”, else were “Past Drinkers”. The
physical activity into three groups based on metabolic equivalents (METs) (active, ≥6;
moderate, ≥4 and <6; and less active, <4).
Fiber intake (grams/day) was assessed based on estimates from the 24-hour
dietary recall. People who had regular dental checkups were defined as those who had
visited a dental clinic at least once in the past year. WC to assess central obesity was
measured using a steel measuring tape to the nearest 0.1 cm at the high point of the iliac
crest at minimal respiration when the participant was in a standing position . Central
adiposity was said to be present if WC was ≥101.6 cm for male subjects and ≥88.9 cm for
female subjects.
Statistical Methods
In this analysis, we excluded insulin users (n=299), pre-diabetic individuals
(n=3334) and those who had no periodontal examination measures (n=1181); hence the
final data for analysis were from 3333 participants.
We used statistical procedures in SAS, version 9.3 (SAS Institute, Cary, NC) to
analyze complex survey using cluster, weight and strata statements, provided by Center
for Disease Control for all the statistical analysis. We calculated the weighted means and
weighted frequencies of serum IgG antibody titers clusters, socio-demographic and other
risk factors according to the tertiles of periodontal clinical measures (accessed by tertiles
of Pocket depth and tertiles of CAL).
To explore the crude association between periodontal clinical measures and the
four z-score clusters of antibody titers, we first ran crude multivariate logistic regression
model. The second model was adjusted for age, sex, race-ethnicity, and income-poverty
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ratio. The third model was additionally adjusted for smoking and drinking alcohol, and
the fourth model additionally included physical activity, WC, BMI, dentist visits, missing
teeth, nutrients including intakes of total energy, fibers, carbohydrate, protein, and fat.
The adjusted odds ratios (ORs), 95% CIs, and P values calculated.
We stratified the analyses described above by tertiles of PD and CAL. To evaluate
possible effect modification we created interaction terms for each of serum IgG clusters
and tertiles of PD and CAL. For example, to evaluate the interaction between OrangeRed cluster and CAL on diabetes the following variables were included in the model: a
multiplicative term between Orange-Red cluster and CAL, scores for all other three
clusters, and covariates including CAL. The interaction was considered statistically
significant if the p-value for the type III analysis of effect for the interaction term was
<0.05.
Results:
Characteristics of the study population across the tertiles of periodontal clinical
measures
The CAL and PD showed positive correlation with Orange-Red and inverse
correlation with Orange-Blue cluster scores (Spearman correlation coefficients are shown
in Table 4.1.
The weighted means (SEs) and weighted frequency percentages of sociodemographic and other potential risk factors are shown in Table 4.2. Orange-Blue cluster
scores decreased across the tertiles of clinical attachment loss (p trend =<0.0001) while
significant trends were not seen in other cluster scores. The mean of Orange-Red cluster
score increased (p trend =0.03) while Orange-Blue cluster scores decreased (p trend=
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0.0095) across the tertiles of pocket depth.
Investigation of confounding and effect modification of clinical periodontal
destruction measures and serum antibody titers in relation to diabetes
The extent of association of serum antibody titers and diabetes in a full model
were not further changed when either of CAL or PD was included (Table 4.3). Hence, no
confounding by clinical periodontal destruction was observed.
The association between diabetes and four serum antibody cluster scores stratified
by tertiles of mean CAL and PD are shown in Table 4.4 and Table 4.5. The relationship
between serum antibody cluster scores and diabetes did not vary when stratified by the
tertiles of CAL (Table4. 4), but approached difference within strata of tertiles of PD
(Table 4.5). The association between the Orange-Blue cluster score and diabetes was
stronger in the highest tertile of PD (ORtertile 1=1.07, 95% CI 0.89, 1.29 versus ORtertile
1=0.74,

95% CI 0.60, 0.91, p-value for interaction 0.07) (Table 5). The positive

association between Orange-Red cluster scores and diabetes likewise seemed stronger in
the highest versus lowest tertiles of PD (Table 4.5). We found the association was
significantly different in the Orange-Red and Orange-Blue clusters by the periodontal
status when periodontal status were defined as moderate or severe if the CAL ≥ 4 mm or
PD ≥ 5mm or else normal. (Appendix A:Table 1).
Discussion:
The association between clusters of IgG antibodies against periodontal
microorganisms and diabetes was stronger among individuals with greater pocket depth
suggesting effect modification by PD; there was no evidence of effect modification of
this association by levels of CAL. The inverse association between the Orange-Blue
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cluster score and diabetes was stronger in the highest versus lowest tertile of mean PD.
Similarly the positive association between the Orange-Red cluster score and diabetes
increased by PD severity. This information is important to consider when information
from clinical and serologic measures of periodontal disease is combined to evaluate their
relation with systemic outcomes.
Serum IgG antibody titers measure the cumulative life time host response due to
persistent infection of periodontitis and/ or the re-occurrence (Papapanou et al. 2004,
Rams, Listgarten, and Slots 2006) which tends to remain stable over a longer periods
even after treatment (Darby, Mooney, and Kinane 2001). Moreover, elevated serum
antibodies titers may not only reflect the protective effect against periodontal disease, but
may also indicate active periodontal lesions, in which case antibody titers would be
indicators of developing periodontal disease (Dye et al. 2009, Lockhart et al. 2012).
Selected serological markers have been used to assess in periodontal disease (Dye et al.
2009). The reasons we used cluster analysis to form 4 groups are, first, periodontal
disease is associated with a shift in balance of microorganisms that are ubiquitous in the
mouth rather than by any single organism. Second, cluster analysis grouped the
antibodies against periodontal microorganisms as they naturally occur is explained in our
previous study. In brief, the Hence by clustering these markers into mutually exclusive
clusters, we can distinguish whether elevated titers are the markers of systemic health or
disease status.
Our findings are consistent with prior reports linking antibodies against
periodontal pathogens and diabetes. In our previous studies, we observed that the OrangeRed cluster of antibodies was positively associated with type 2 diabetes and
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hyperglycemia, while the Orange-Blue cluster of antibodies showed an inverse relation. .
The Orange-Red cluster included serum antibodies against P. gingivalis and Prevotella
sps. The Orange-Blue cluster included E. nodatum and A. naeslundii. In this current
study, no notable relationship was observed in Red-Green and Yellow-Orange Clusters.
There are evidences that the elevated antibody titer of some selected bacteria in these
clusters is linked to diabetes. The periodontal bacteria of Red-Green cluster score;
particularly A. actinomycetemcomitans has previously shown inconsistent association
with other systemic disease (Hosomi et al. 2012, Pussinen et al. 2005). Studies have
reported that periodontal pathogens P. gingivalis and Prevotella sps and their serum
antibodies titers are higher in individuals with type 2 diabetes (Casarin et al. 2013,
Darveau 2010, Darveau, Hajishengallis, and Curtis 2012, Desvarieux et al. 2013, Dye et
al. 2009). Although the E. nodatum organism is associated with periodontal destruction,
elevated antibody titers against E. nodatum are associated with periodontal health (Dye et
al. 2009). Higher concentration of A. neslundii has been associated with periodontal
health (Williams, Pantalone, and Sherris 1976, Dye et al. 2009, Desvarieux et al. 2005).
A recent study reported effect modification of the relation between periodontal damage
and diabetes by levels of serum CRP, and antibody titers against periodontal pathogens
particularly P. gingivalis and A. actinomycetemcomitans.
In the present analyses we have built on findings linking antibodies against
periodontal pathogens and diabetes by studying their interaction with clinically
determined periodontal destruction. Periodontal destruction has being linked to an array
of chronic diseases including hyperglycemia through systemic inflammation
(Oppermann, Weidlich, and Musskopf 2012, Mustapha et al. 2007, Ebersole et al. 2008,
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Brito et al. 2013). Although unclear, there are four biologically meaningful hypotheses
(common susceptibility, systemic inflammation, direct infection of blood vessels and the
cross-reactivity or molecular mimicry) that explain possible mechanisms kinking
periodontal infection with systemic disease in different people (Seymour et al. 2007,
Seymour et al. 2009). Understanding the interaction between the clinical periodontal
destruction, microbiological, serological periodontal parameters will be useful to
minimize bias and spurious relationship while exploring the complex systemic
relationship.
This present study has some drawbacks. First, in NHANES III (1988-1994),
periodontal examination (CAL and PD) was measured on only 2 sites in each tooth which
might underestimate the prevalence and severity of periodontal disease (Papapanou
2012). Although, we measured most of the potential confounders that were examined and
measured in this dataset, there could be some unmeasured confounding factors such as
oral hygiene that could bias this cross-sectional analysis. Additionally, we studied the
commonly identified serum IgG antibody titers of 19 periodontal bacteria but those
unidentified and unknown periodontal microbes may change the pattern of clusters hence
we recommend this study findings needs to validated in recent population using
sophisticated techniques and epidemiological methods. Despite limitations, this study has
generated a hypothesis that combination of selected serological markers and clinical
assessment of periodontal destruction increase the prediction of the diabetes.
The relation between IgG antibody groups and diabetes was found to vary by
tertiles of periodontal pocket depths. This finding is relevant when clinical parameters
and periodontal antibodies are studied in combination in relation to systemic disease.
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Table 4.1: Correlation of the z-scores of serum antibody clusters with clinical attachment
loss and pocket depth
Spearman’s
correlation
(n=3333)
CAL
PD

PD

0.57**
-

Red-Green

Orange-Red

YellowOrange

Orange-Blue

-0.02
-0.02

0.07**
0.11**

-0.03
-0.02

-0.13**
-0.07**

** p value <0.0001
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Table 4.2: Profile characteristics of study population sample across tertiles of clinical periodontal measures

(Total n=3333)
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Sex: %
Male
Female
Race/ Ethnicity %
Non-Hispanic
Whiles
Non –Hispanic
Blacks
Mexican
American
Others
Education %
≤ 6 years
7 – 12 years
≥ 13 years
Income to poverty
ratio %
Lower (≤1.5)
Middle (≤3.0)
Higher (>3.0)
Smoking %
Never
Past
Current
Alcohol intake %

Clinical Attachment loss (CAL)
Tertile1
Tertile II
Tertile III
(n=1188)
(n=1136)
(n=1009)
40.1
59.9

44.3
55.7

58.2
41.8

84.5
6.3
3.5
5.7

81.3
6.5
3.6
8.5

79.1
10.4
3.7
6.8

3.21
38.1
58.7

4.4
52.5
43.1

10.6
23.3
63.1

P value

Tertile1
(n=1111)

Pocket Depth (PD)
TertileII
Tertile III
(n=1163)
(n=1059)

P Value
<0.0001

<0.0001

39.1
60.9

45.8
54.2

57.1
42.9

0.0734

86.2
4.4
2.6
6.8

82.2
7.2
3.8
6.8

75.2
12.5
4.8
7.5

<0.0001

8.1
61.8
30.1

<0.0001

3.5
42.2
54.3

4.1
47.5
48.4

7.9
61.3
30.9

<0.0001

14.2
25.3
60.5

20.0
35.6
44.4

<0.0001

11.5
26.6
61.9

12.2
27.0
60.8

21.1
32.2
46.7

<0.0001

55.5
33.9
10.6

37.2
47.1
15.7

24.3
50.0
25.7

<0.0001

50.4
3805
11.1

40.6
43.9
15.5

29.0
46.4
24.6

<0.0001

14.0

14.4

12.2

0.3813

14.8

12.7

13.4

0.1986
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Never
Past
Current
Physical activity
%
Sedentary
Moderately active
Vigorously active
Missing
No of missing
teeth, %
“0”
“1-5”
“6-10”
“>10”
Waist
Circumference
Normal
Elevated
Annual visits to
dentist %
Yes
No
Diabetes %
Normal
Mean (Se)
Age, years, mean
(se)
Fiber intake,
g/day, mean (se)

32.5
53.5

31.4
54.2

37.4
50.4

34.9
50.3

29.8
57.5

35.4
51.2

57.5
12.9
8.3
21.3

54.7
13.1
8.0
24.1

54.0
11.3
5.8
28.9

0.1336

55.4
15.0
9.0
20.6

57.2
11.6
7.3
23.9

54.1
10.0
5.8
30.2

0.0027

56.1
37.3
5.4
1.1

40.0
49.8
9.2
0.9

35.1
41.2
17.7
5.9

<0.0001

51.4
39.6
7.8
1.2

42.3
47.5
8.8
1.3

40.6
40.6
13.8
5.0

<0.0001

58.3
41.7

56.7
43.3

49.7
50.3

0.0270

60.4
39.6

55.5
44.5

48.2
51.8

0.0013

71.2
28.7

65.1
34.9

48.9
51.1

<0.0001

72.8
27.2

65.8
34.1

46.0
54.0

<0.0001

8.9
91.1

11.3
88.7

25.2
74.8

<0.0001

10.1
89.9

12.9
87.1

20.5
79.5

<0.0001

49.1±0.5

53.9±0.6

59.0 ± 0.6

<0.0001

52.5 ±0.5

53.3 ±0.4

53.8 ±0.5

0.0892

27.04±0.3

27.1±0.3

27.1±0.2

0.0528

26.4±0.2

27.1±0.3

28.1±0.3

0.0834

Carbohydrate
Intake, g/day
mean (se)
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258.9±5.5

248.8±5.2

243.4±7.6

0.04

249.3±5.2

254.3±5.1

252.2±9.0

0.69

Protein Intake,
g/day mean (se)

79.7±1.8

77.8±1.8

77.5±1.9

0.35

76.2±1.7

79.0±1.8

81.7±2.1

0.07

Fat Intake, g/day
mean (se)

80.4±2.6

77.7±2.3

75.3±2.1

0.10

76.5±2.2

80.0±2.1

78.9±2.2

0.41

17.9±0.5

17.1±0.5

16.4±0.4

0.8527

17.7±0.5

17.4±0.4

16.3±0.6

0.0002

0.50 ± 0.4
-0.30 ± 0.2
0.43 ± 0.3
0.51 ± 0.1

-0.20 ± 0.4
-0.14 ± 0.1
0.07 ± 0.3
0.28 ± 0.1

-0.39 ± 0.5
-0.12 ± 0.2
-0.35 ± 0.4
-0.13 ± 0.1

0.0338
0.4487
0.0496
<0.0001

0.38 ± 0.4
-0.37 ± 0.2
0.26 ± 0.3
0.39 ± 0.1

-0.10 ± 0.5
-0.26 ± 0.2
0.07 ± 0.3
0.26 ± 0.1

-0.31 ± 0.4
0.15 ± 0.2
-0.03 ± 0.2
0.13 ± 0.1

0.0755
0.0264
0.2896
0.0026

BMI, kg/m2, mean
(se)
Red-Green
Orange-Red
Yellow-Orange
Orange-Blue

Table 4.3: Exploring confounding effect (Odds Ratio and 95%CI) of clinical periodontal measures in the relation to serum antibody
clusters and diabetes
(n=3333)

Red-Green

Orange-Red

Yellow-Orange

Orange-Blue

Adjustment for age, sex,
education, ethnicity, smoking ,
drinking alcohol, physical
activity, BMI WC, missing teeth
and dentist visit
(Reference full model)

0.98
(0.92 ,1.03)

1.04
(0.98, 1.09)

1.05
(0.97, 1.14)

0.893
(0.81, 0.99)

0.97
(0.922, 1.036)
0.98
(0.92, 1.04)

1.03
(0.968, 1.086)
1.03
(0.97, 1.09)

1.06
(0.98, 1.14)
1.06
(0.98, 1.14)

0.90
(0.81, 0.99)
0.89
(0.80, 0.99)

Additionally adjusted for CAL
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Additionally adjusted for PD

Table 4.4: Association of the z-scores of serum antibody clusters with diabetes stratified by the tertiles of clinical attachment loss
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Serum Antibody
Odds Ratio (95% Confidence Interval)
z-scores Clusters
Clinical Attachment Loss
Model*
Tertile I
Tertile II
Tertile III
Red-Green
Model1
1.01 (0.93, 1.10)
1.01 (0.91, 1.13)
1.01 (0.93, 1.09)
Model2
1.06 (0.94, 1.18)
0.96 (0.88, 1.06)
0.99 (0.92, 1.07)
Model3
1.03 (0.91, 1.15)
0.96 (0.87, 1.06)
0.99 (0.93, 1.08)
Model4
1.04 (0.92, 1.18)
1.01 (0.88, 1.66)
0.95 (0.86, 1.05)
Orange-Red
Model1
1.08 (0.99, 1.18)
1.09 (0.98, 1.20)
1.21 (1.08, 1.36)*
Model2
1.08 (0.96, 1.23)
1.04 (0.95, 1.13)
1.05 (0.95, 1.17)
Model3
1.06 (0.91, 1.24)
1.03 (0.94, 1.14)
1.06 (0.96, 1.16)
Model4
1.001 (0.83, 1.15)
0.98 (0.88, 1.10)
1.07 (0.98, 1.16)
Yellow-Orange
Model1
0.94 (0.82, 1.07)
0.97 (0.87, 1.08)
0.97 (0.88, 1.07)
Model2
0.94 (0.83, 1.07)
1.03 (0.92, 1.13)
1.00 (0.91, 1.10)
Model3
1.02 (0.89, 1.15)
1.03 (0.93, 1.15)
0.99 (0.91, 1.10)
Model4
1.05 (0.90, 1.22)
1.02 (0.88, 1.18)
1.08 (0.96, 1.20)
Orange-Blue
Model1
0.88 (0.76, 1.01)
0.97 (0.86, 1.09)
0.82 (0.70, 0.96)*
Model2
0.91 (0.77, 1.07)
0.95 (0.82, 1.09)
0.98 (0.86, 1.12)
Model3
0.88 (0.74, 1.04)
0.94 (0.83, 1.07)
0.99 (0.86, 1.13)
Model4
0.87 (0.72, 1.04)
0.87 (0.73, 1.04)
0.95 (0.78, 1.15)
Model 1: adjusted for the clusters.
Model 2: Model 1 plus additionally adjusted for age, sex, education, income, race
Model 3: Model 2 plus additionally adjusted for smoking, alcohol intake
Model 4: Model 3 plus additionally adjusted further with missing teeth, dental visit, BMI, central adiposity, physical activity, total
energy, carbohydrate, fat and protein intake.* p value <0.05

Table 4.5: Association of the z-scores of serum antibody clusters with diabetes stratified by the tertiles of clinical pocket depth
measures
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Serum Antibody Clusters
Odds Ratio (95% Confidence Interval) Pocket Depth
Model*
Tertile I
Tertile II
Tertile III
Red-Green
Model1
0.98 (0.88, 1.08)
1.05 (0.93, 1.18)
1.07 (0.97, 1.19)
Model2
0.97 (0.87, 1.07)
1.02 (0.90, 1.15)
1.03 (0.92, 1.15)
Model3
0.97 (0.87, 1.08)
1.02 (0.90, 1.13)
0.97 (0.86, 1.11)
Model4
0.92 (0.82, 1.03)
1.04 (0.91, 1.17)
0.97 (0.84, 1.12)
Orange-Red
Model1
1.10 (0.99, 1.22)
1.16 (1.05, 1.29)*
1.13 (1.03, 1.23)*
Model2
1.01 (0.91, 1.13)
1.03 (0.94, 1.13)
1.12 (1.00, 1.26)*
Model3
0.99 (0.88, 1.12)
1.03 (0.94, 1.12)
1.15 (1.01, 1.31)*
Model4
0.97 (0.86, 1.09)
1.03 (0.94, 1.14)
1.10 (0.95, 1.28)
Yellow-Orange
Model1
0.99 (0.89, 1.10)
0.96 (0.86, 1.06)
0.92 (0.80, 1.05)
Model2
1.05 (0.91, 1.13)
0.99 (0.89, 1.09)
0.97 (0.83, 1.12)
Model3
1.05 (0.94, 1.16)
0.98 (0.88, 1.08)
1.04 (0.87, 1.24)
Model4
0.97 (0.87, 1.09)
1.10 (0.89, 1.36)
1.13 (1.01, 1.27)
Orange-Blue
Model1
0.94 (0.80, 1.09)
0.80 (0.70, 0.89)*
0.86 (0.73, 0.99)*
Model2
1.06 (0.89, 1.26)
0.88 (0.77, 1.00)
0.89 (0.77, 1.04)
Model3
1.06 (0.87, 1.29)
0.88 (0.78, 0.99)*
0.84 (0.70, 0.99)*
Model4
1.07 (0.89, 1.29)
0.84 (0.72, 0.98)*
0.74 (0.60, 0.91)*
Model 1: adjusted for the clusters. Model 2: Model 1 plus additionally adjusted for age, sex, education, income, race
Model 3: Model 2 plus additionally adjusted for smoking, alcohol intake
Model 4: Model 3 plus additionally adjusted further with missing teeth, dental visit, BMI, central adiposity, physical activity, total
energy, carbohydrate, fat and protein intake.* p value <0.05
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Relationship between serological markers of periodontal bacteria and metabolic
syndrome and its components
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Abstract:
Metabolic syndrome (MetS), a complex cluster of cardiovascular risk factors, has
been linked to periodontal diseases; however the contribution of periodontal bacteria to
systemic conditions remains unclear. We studied the magnitude and extent of the relation
between serum IgG antibody titers against periodontal bacteria and MetS and its
individual components.
The study population comprised of 7848 US adults who participated in an
interview, clinical, oral health examination, and had serum IgG titers measured against 19
periodontal bacteria as part of the NHANES III survey. The z-scores antibody titers were
clustered into 4 mutually exclusive groups and named after Socransky’s classification of
periodontal bacteria (Orange-Red, Red-Green, Yellow-Orange, and Orange-Blue).
Survey logistic regression was used to investigate the independent associations between
the cluster scores, and MetS and each component including hypertension,
hypertriglyceridemia, low HDL-cholesterol, central obesity, and elevated fasting glucose.
The Orange-Red cluster score (associated with periodontal disease) was positively
associated [OR: 1·067 (1·02-1·12)]) and Orange-Blue cluster score inversely associated
[OR= 0·93 (0·88-0·97)] with elevated fasting glucose (≥110 mg/dl) after adjusted for
clusters and potential confounders. Neither MetS nor its other remaining MetS
components were associated with a particular cluster score.
The associations between different antibody clusters against periodontal bacteria
and elevated plasma glucose were in qualitatively opposite directions after multivariable
adjustment in a large, adult population. The periodontal bacterial profile was not found

130

associated with metabolic control other than very moderate association with elevated
plasma glucose.
Keywords: Metabolic syndrome, hypertension, hyperlipidemia, central obesity, elevated
fasting plasma glucose, serum immunoglobulinG (IgG), periodontal microbiota
Introduction:
Periodontitis is a chronic poly bacterial infection in the tooth-supporting tissues,
which may lead to tooth loss. Isolation of selected periodontal pathogens such as
Porphyromonas gingivalis, Prevotella intermedia, Eikenella corrodens, Treponema
denticola, Campylobacter rectus from atherosclerotic lesions in humans and animals,
(Kebschull, Demmer, and Papapanou 2010) and the positive association of higher titers
of antibodies against P gingivalis with coronary heart disease (Yamazaki et al. 2007),
stroke (Pussinen, Alfthan, et al. 2007), and myocardial infraction (Holmlund et al. 2011)
raised attention to the potential role of periodontal organisms in systemic conditions .
Recently, a longitudinal study findings showed that improved clinical and microbial
periodontal profile reduced the progression of carotid atherosclerosis over three years
(Desvarieux et al. 2013). These microbiological and, serological evidences (Mustapha et
al. 2007) have generated interest to better understand related factors underlying the
relationship between periodontal disease and cardiovascular disease (CVD), including
chronic inflammation, diabetes and the metabolic syndrome (MetS).
Diabetes and periodontal disease are common in middle aged persons, share
common risk factors (Taylor, Preshaw, and Lalla 2013), are associated with CVD
(Lockhart et al. 2012, Southerland et al. 2012), risk markers of CVD (Oldridge et al.
2001), systemic inflammation (Oppermann, Weidlich, and Musskopf 2012), and
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metabolic syndrome (MetS) (Alberti et al. 2009). Diabetes and pre-diabetes prevalence is
higher among individuals with more severe periodontal disease (Choi et al. 2011).
However, the role that periodontal microorganisms play in these relationships is
incompletely understood. A clear insight into this relationship has potential for the
development of targeted strategies to prevent and manage these conditions.
In the previous observations, we found that antibody titers against selected
periodontal microorganisms group into 4 distinct clusters, and that these are related to
diabetes and pre-diabetes in the third National Health and Nutritional Examination survey
(NHANES III). In this present study, we aimed to investigate the extent to which clusters
of serum IgG antibodies against periodontal bacteria were related to MetS and its
individual components including hypertension, hypertriglyceridemia, low high density
lipoprotein (HDL)-cholesterol, central adiposity, and elevated plasma glucose. MetS
intends to identify those who are at risk stage of cardiovascular disease, pre-diabetes, or
diabetes (Alberti et al. 2009). We hypothesized that specific subsets of serum IgG
antibodies against periodontal bacteria were linked to periodontal health or disease could
associated with metabolic control.
Materials and Methods:
Data Source:
The study population consisted of participants of the NHANES III (1988-1994)
survey who were ≥40 years old, and had complete data for serum IgG antibody titers
against 19 oral bacteria (n=8153); we excluded those who used insulin (n=299) and/or
had gestational diabetes (n=6); leaving 7848 participants for the final analysis. The
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NHANES III sample is representative of the non-institutionalized US population;
information is collected through interviews, medical and dental examinations, and
laboratory tests. The de-identified data are available at:
http://www.cdc.gov/nchs/nhanes/nh3data.htm. For this study we merged the following
datasets: Periodontal Pathogens (SPSDEPPX), Household Adult Data File (Catalog
Number 77560), NHANES III Examination Data File (Catalog Number 76200);
NHANES III Laboratory Data File (Catalog Number 76300); NHANES III Dietary
Recall Data Files (Catalog Number 76700) using unique de-identified respondent
identification numbers.
Assessment of Outcome
The outcomes were each of five components of metabolic syndrome consistent
with recent task force guidelines (Alberti et al. 2009): elevated central obesity,
hypertriglyceridemia, low HDL cholesterol, high blood pressure, and high elevated
fasting glucose. We categorized these variables after excluding implausible values.
Central obesity was categorized as elevated if waist circumference was ≥ 90 cm for men
and ≥ 85 cm for women, else normal. Hypertension was defined as present if systolic
blood pressure was > 130 mm Hg or Diastolic blood pressure was > 85 mm Hg or if the
participant reported taking anti-hypertensive medication, or absent otherwise.
Hypertriglyceridemia was defined as present if triglycerides were >150 mg/dl or else
normal. High density lipoprotein was categorized as low if HDL was < 40mg/dl for men
and <50 mg/dl for women or optimum otherwise. Elevated plasma glucose was defined
as present if fasting plasma glucose was >100 g/dl or else normal. Additionally,
participants were assessed as having MetS if they had at least three of these components
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(Alberti et al. 2009).
IgG assay for periodontal bacteria
Stored sera of NHANES III participants, aged 40 years or older were analyzed for
IgG antibodies against 19 oral bacterial species, and the data released in 2008 (N=8153).
The following 19 bacterial strains were used to prepare whole cell antigenic extracts by
checkerboard immunoassay: Aggregatibacter actinomycetemcomitans (ATCC strains
#43718, #29523 and #33384); Porphyromonas gingivalis (ATCC #33277 and #53978);
Tannerella forsythia (ATCC#43037); Treponema denticola (OMGS#3271);
Campylobacter rectus (ATCC#33238); Eubacterium nodatum (ATCC#33099);
Prevotella intermedia (ATCC#25611); Prevotella nigrescens (ATCC#33563); Prevotella
melaninogenica (ATCC#25845); Fusobacterium nucleatum (ATCC#10953);
Micromonas micros (ATCC #33270); Selenomonas noxia (ATCC#43541); Eikenella
corrodens (ATCC#23834); Capnocytophaga ochracea (ATCC#33624); Streptococcus
intermedius (ATCC#27335); Streptococcus oralis (ATCC#35037); Streptococcus mutans
(ATCC#25175); Veillonella parvula (ATCC#10790); and Actinomyces naeslundii
(ATCC#49340). The Oral and Diagnostic Sciences Laboratory, Columbia University
College of Dental Medicine analyzed the sera The using the ‘‘checkerboard’’
immunoassay technique measured in gravimetric units. The detailed procedure is
described in NHANES III documentation:
ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/nhanes/nhanes3/30a/spsdeppx.pdf
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Definition of the periodontal exposures
The IgG antibody titers were log transformed and then converted to standardized
z scores (Desvarieux et al. 2010). Participants with hyperglycemia (HbA1c ≥ 5.7) were
included in cluster analysis to derive four mutually distinct groups of periodontal
bacteria. The z-scores against periodontal bacteria in the respective clusters were summed
to obtain cluster scores for each group. These four cluster scores [Orange-Red, RedGreen, Yellow-Orange, and Orange-Blue] were named according to Socransky’s color
classification scheme (Figure 3.1) (Socransky and Haffajee 2002).
Covariate Information
Demographic, lifestyle and anthropometric measures included gender, age,
race/ethnicity, education, income-poverty ratio, smoking and alcohol drinking habits,
physical activity, fiber intake, frequency of regular dentist visits, waist circumference
(WC), body mass index (BMI), and diabetes. Race/ethnicity was self-reported and was
divided into four groups: non-Hispanic white, non-Hispanic black, Mexican American
and others. Income was grouped into three groups of the income-to-poverty ratio (≤1.5,
>1.5 to ≤3.0, and >3.0), education level into three groups ≤6 years; 7 to 12 years; and ≥13
years).
Smoking status was classified into three groups (current, past and never smokers).
Alcohol consumption was divided into three groups (current, past and never alcohol
drinkers). Physical activity was divided into three groups based on metabolic equivalents
(METs) (active, ≥6; moderate, ≥4 and <6; and less active, <4) (Choi et al. 2011).
Fiber intake was assessed based on estimates from 24-hour dietary recall data.
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People who had regular dental checkups were defined as those who had visited a dental
clinic at least once in the past year. WC to assess central obesity was measured using a
steel measuring tape to the nearest 0.1 cm at the high point of the iliac crest at minimal
respiration when the participant was in a standing position (Choi et al. 2011). Central
adiposity was said to be present if WC was ≥101.6 cm for male subjects and ≥88.9 cm for
female subjects. WC was not included in final adjusted model where WC was the
outcome variable and similarly, diabetes was not used as confounder when elevated
plasma glucose was the outcome variable. We defined diabetes status as diabetes, prediabetes and normal blood glucose level. Pre-diabetes was defined as having HbA1c 5.7 to
<6.5% or fasting plasma glucose (FPG) 100 to <126 mg/dl (5.6-6.9 mmol/L). Individuals
with HbA1c ≥ 6.5% or FPG ≥ 126 mg/dl [7 mmol/L] or those who self-reported
diagnosed diabetes were classified as having diabetes or else classified as normal blood
glucose level(Bullard et al. 2013).
Statistical Methods
SAS, version 9.3 (SAS Institute, Cary, NC) was used for data management and
statistical analyses. SAS survey procedures were used to take into account the complex
weighted sampling design and yielded unbiased parameter estimates and standard errors.
Sample weights, cluster, and strata variables provided by CDC were used. A statistically
significant α level was considered at 0.05.
Descriptive statistics were estimated using procedures for complex surveys in SAS (proc
surveymeans and proc surveyfreq). The distribution of socio-demographic, lifestyle,
anthropometric and outcome measures across tertiles of cluster scores were estimated.
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Using the survey regression multivariable model, we then regressed each of these
outcomes with the four z-score clusters. Secondly, the model was adjusted for age
(continuous) and sex. Thirdly, we adjusted further for race and ethnicity, income-poverty
ratio, smoking, alcohol, physical activity, fiber intake (continuous), dentist visits, WC
and BMI (continuous). In the fourth model, diabetes status was further added in the
analysis of hypertension, hyper triglycerides, low HDL-cholesterol, and central adiposity.
Results:
In this population, 37·8% had low HDL-cholesterol, 37·4% hypertriglyceridemia,
60.02% hypertension, 52.01 % elevated central adiposity, 38.2 % elevated plasma
glucose and 41.8% MetS. The adverse health conditions were generally more common
among Non-Hispanic Whites, females, high school graduates (7-12 years education
level), never or past smokers, current or former alcohol drinkers, individuals who were
hypertensive, overweight, sedentary, and who did not have annual dental visits. The
characteristics of the study population across extreme tertiles of four cluster scores are
shown in Table 5.1. There were some notable differences in participant characteristics
across Orange-Red and Orange-Blue clusters. The top tertile of Orange Red cluster
(which included P gingivalis and Prevotella species) had larger proportions of
individuals who were male, less educated, low income, Non-Hispanic Black, never
smokers, normal triglycerides, hypertensive and insulin resistant compared to the lowest
tertile; the highest tertile of the Orange-Blue cluster (which included A naeslundii and E
nodatum) had individuals who were highly educated, high income, Non-Hispanic White,
never smokers, current drinkers, visited the dentist regularly at least once a year, and had
optimum high density lipoproteins, tri-glyceride and blood glucose levels. There were
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higher proportions of individuals with diabetes and pre-diabetes in the top versus bottom
tertiles (11·2 vs 8·1) in the Orange-Red cluster, however the opposite trend for diabetes
(8·6 vs 11·1) was observed in the Orange-Blue cluster; no such differences were seen in
other clusters (Table 5.1).
Correlations between clusters scores are shown in Table 5.2. The highest
correlation is in between Yellow-Orange (predominantly Streptococcus sps) and RedGreen (T denticola, T forsythia, A actinomycetemcomitans and others) scores (0·91, p
value=<0·0001) whereas lowest is in between Orange-Red and Orange-Blue clusters
(0·34, p value=<0·0001). Mean values of serum IgG z-scores of four clusters by different
outcome measures are shown in Table 3. Only Orange-Red scores were higher in
individuals having MetS and those with elevated plasma glucose levels; increased
Orange-Blue scores were observed in individuals who had no hypertension and normal
plasma blood glucose.
After full adjustment of potential confounders, no association was seen in four
cluster scores with MetS and any of the individual components except for elevated
plasma glucose. For each unit increase in Orange-Red cluster scores the odds of elevated
plasma glucose 6% [OR: 1·06 (1·02-1·10)] with; with the National Cholesterol Education
Program (NCEP)-Adult treatment panel III criteria (elevated plasma blood glucose level,
≥110 mg/dl) (Lorenzo et al. 2007)(17)(Lorenzo et al. 2007)(Lorenzo et al. 2007) there
were 7% higher odds [OR: 1·06 (1·02-1·12)] and 1 unit higher Orange-Blue cluster score
was associated with 7% lower odds of hyperglycemia [OR:0·93 (0·88-0·98)]. No
association was seen with Orange-Red and Yellow-Orange cluster scores (Table 5.4).
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Similar analyses conducted among people with no missing teeth yielded qualitatively
similar results (Table 5.5).
Discussion:
Elevated plasma glucose was more common among individuals with higher serum
IgG antibody titer scores against organisms belonging to the Orange-Red cluster
(indicating periodontal disease), and lower in titer scores against organisms from the
Orange-Blue cluster after adjustment for several socio-demographic, anthropometric and
behavioral factors. There was no association between antibody score clusters and MetS or
other individual components of MetS (hypertension, dyslipidemia, central obesity).
Periodontitis is not due to a single pathogen, but results from a complex
biological alteration of the periodontal microenvironment, and a distributional shift of
key periodontal pathogens(Berezow and Darveau 2011). Ebersole et al (Ebersole et al.
2008) postulated that increased severity may be due to alterations in the pathogenicity of
the periodontal bacteria in the plaque biofilm, which in turn may imbalance the host
immune system and impact systemic inflammation. Although there is biological
plausibility for the hypothesis, some study findings refute a causal role of direct
periodontal pathogen invasion in the systemic disease (Lockhart et al. 2012). Moreover,
periodontal pathogen coexists with hundreds of others, making it difficult to isolate the
potential effect of a particular pathogen, and predisposing such studies to type 1 error
(Wang et al. 2007). To overcome this limitation investigators have grouped the
periodontal organisms together either using empirical (Socransky and Haffajee 2002) or
theoretical (Desvarieux et al. 2013) approaches. Socransky et al grouped pathogens
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related to periodontal disease status, while Desverieux et al grouped the periodontal
organisms that were hypothesized to be related to cardiovascular disease. Similar
analyses for type 2- diabetes were not found in the literature.
In the current study, we used an empirical approach to cluster oral pathogens
among individuals with hyperglycemia and measured the extent of association of these
clusters with metabolic control. This was an appropriate method to classify antibodies
against the 19 oral microorganisms because the microorganisms are correlated with each
other and their roles are not yet clearly defined. We obtained cluster scores by summing
z-scores of the titers because we were interested in evaluating the relative (rather than
absolute) contributions of the titers to the overall score.
Both the total study participants (Table 5.4) as well as only dentate (Table 5.5),
the Orange-Red cluster (associated with periodontal disease) include antibody titers
against P.gingivalis and Prevotella sps and increased the odds while the elevated serum
IgG antibody against Orange-Blue cluster score that included E. nodadum and A.
naeslundii antibody lowered the odds of having elevated plasma glucose. This
relationship was more distinct when elevated plasma level cut point was >110 mg/dl
which will include only diabetes population. P.gingivalis and Prevotella sps have been
consistently associated not only with periodontal disease status but also different
systemic diseases such as CVD, diabetes or arthritis. A. naeslundii has been consistently
related to healthy periodontal and systemic states (Socransky and Haffajee 2002,
Desvarieux et al. 2013). One study has reported higher microbial count of E. nodatum
associated with periodontitis lesions (Haffajee, Teles, and Socransky 2006) but the
antibody titers against E. nodatum were associated with periodontal health (Dye et al.
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2009). No prior studies used cluster methodology to study the relationship in past
literatures; hence we could not compare our study findings with other studies. Clinically,
periodontitis is diagnosed only for the dentate individuals. However, serum antibody
titers against the periodontal bacteria may reflect current or past exposures to periodontal
bacteria, hence measures the cumulative life time exposures. Excluding edentulous
individuals did not alter the results (Table 5.5). There was no significant finding when the
association was observed using three groups (Etiologic, putative and Health) (Table 5.6).
Prior studies reported an association of periodontal disease independently with
MetS (Nibali et al. 2013) and their individual components including hypertension
(Desvarieux et al. 2010), hyperlipidemia (Moeintaghavi et al. 2005)and central
obesity(Kim, Jin, and Bae 2011). Periodontal disease in these studies was assessed by
clinical measures index (such as clinical attachment loss or pocket depth). In the current
study, upon full adjustment for potential confounders, no association was seen with
serological markers of periodontal bacteria with MetS and any of other MetS (Table 5.4
and 5.5). However, Pussinen et al., (2003) (Pussinen et al. 2003) reported the
combination of serum IgG antibodies against P. gingivalis and A. actinomycetemcomitans
had inverse association with serum HDL concentration.
This present study has some drawbacks. First, the cross-sectional design does not
explain when the serum IgG antibody titer response evolved. Second is the possibility of
unmeasured confounding factors because oral health behaviors were not evaluated. Third,
this study evaluates 19 antibodies against periodontal microbiota; hence additional
pathogens could modify the overall relationship. Research finding has shown that
presence of high virulence strain of P. gingivalis may affect CHD (Yamazaki et al. 2007),
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so use of serum antibody titers against P. gingivalis mixture and A.
actinomycetemcomitans mixture could underestimate our analysis. Fourth, although
highly sensitive C-reactive protein (Hs-CRP) is an indicator of systemic inflammation,
we did not adjust for it or clinically defined periodontitis because they may be on the
causal pathway and would create bias (Cole and Hernan 2002).
The strengths of this study were first, this was a large, representative, population
based sample, with careful measurement of potential confounders, reducing the
likelihood of false negative or spurious results. To our knowledge, this is the largest study
to evaluate the relation between titers against oral microorganisms and MetS and its
individual components. Second, we adjusted for a number of potential confounders.
Third, serum IgG antibody titers measure persistent periodontal infection and/ or
recurrence, (Papapanou et al. 2004, Rams, Listgarten, and Slots 2006); these serum IgG
measures are a therefore a measure of cumulative life exposure to periodontal diseases.
Fourth, cluster analysis resulted in reduced data and mutually exclusive groups,
minimizing the chance of spurious results from multiple testing. Fifth, in the
multivariable models we evaluated the clusters together. This approach mimics the
biological processes that take place in the mouth because oral microorganisms are
ubiquitous, and changes in microbial composition occur relative to other organisms in the
mouth. Thus, the relative composition oral microorganisms may tilt the balance between
health and disease (Socransky and Haffajee 2002, Oppermann, Weidlich, and Musskopf
2012). Sixth, empirical clustering of serum IgG reduces the influence of individual
antibody titers, making it a more stable measure of cumulative exposure to periodontal
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pathogens, and possibly advantageous in the study the periodontal-systemic disease
relations.
In summary, we found that antibodies against periodontal microorganisms were
moderately associated with elevated plasma glucose but not with MetS or its other
components. These findings together with emerging evidence that gut microbiota are
correlated with MetS traits (Zupancic et al. 2012), are motivation for the conduct of
sophisticated longitudinal studies with clinical, microbiological and immunological data
to increase our understanding the relation between microorganisms in the mouth and gut
and the metabolic state. This may lead to new approaches to address these conditions.
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Table 5.1: Profile characteristics of metabolic syndrome components in lower vs upper tertiles of four cluster scores
Variables
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Sex (%)
Male
Female
Education (%)
≤ 6 years
7 – 12 years
≥ 13 years
b
Income to poverty ratio
Lower (≤1.5)
Middle (≤3.0)
High (>3.0)
Race/ethnicity (%)
Non-Hispanic Whites
Non-Hispanic Blacks
Mexican Americans
Other
Cigarette Smoker (%)
Never smoker
Past smoker
Current Smoker
Alcohol (%)
Never drinker
Past drinker
Current drinker
Dentist visit once in year
(%)

a

n

Orange-Red
Tertile1 Tertile3

Red-Green
Tertile1 Tertile3

Yellow-Orange
Tertile1 Tertile3

Orange-Blue
Tertile1 Tertile3

3677
4171

40.1
59.9

50.3
49.7

41.3
58.7

49.8
50.2

42.9
57.1

47.0
52.4

45.9
54.1

46.7
53.3

1403
4344
2046

5.5
57.2
37.3

9.2
52.1
38.7

5.7
58.5
35.8

7.3
50.5
42.3

7.0
58.6
34.4

7.1
52.0
40.9

7.9
58.7
33.4

5.1
49.3
45.6

2387
2214
2496

18.5
28.8
52.7

20.6
28.8
50.6

19.3
30.6
50.1

17.7
30.4
51.9

22.4
28.8
48.8

18.4
30.8
50.8

22.8
33.0
44.1

15.0
27.2
57.8

4012
1817
1699
320

87.6
5.6
2.2
4.6

71.9
13.4
4.9
9.8

85.8
6.8
2.8
4.6

76.2
10.8
4.1
8.9

84.0
7.4
2.9
5.7

76.7
11.2
3.8
8.3

80.4
9.8
3.1
6.7

82.6
8.3
3.6
5.5

3562
2521
1765

39.5
33.2
27.3

46.3
35.5
18.2

37.5
34.2
28.3

45.9
36.7
17.4

38.7
33.3
28.0

45.7
35.3
19.0

38.6
32.7
28.7

46.5
35.4
18.1

1480
3185
3031

15.6
38.3
46.1

15.7
37.4
46.9

14.7
38.5
46.7

16.1
38.9
45.0

15.2
38.7
46.1

16.2
37.6
46.2

17.2
39.6
43.2

13.6
38.3
48.1

3010

51.7

52.0

49.4

52.2

48.1

54.6

47.9

55.3

145

Yes
No
Physical Activity (%)
Sedentary
Active
Vigorously active
c
Central Obesity (%)
Normal
Elevated
High density lipoproteins
(%)
Normal
Lower
Triglycerides (%)
Normal
High
Hypertension (%)
Yes
No
Insulin Resistance (%)
Yes
No
Metabolic Syndrome (%)
Yes
No
Diabetes Status (%)
Diabetes
Pre-diabetes
Normal

4588

48.2

8.1

50.6

47.8

51.9

45.4

52.0

44.7

3550
927
500

53.6
12.3
6.8

51.7
11.4
7.8

54.4
11.1
7.2

50.3
12.3
7.8

51.6
12.0
7.6

50.5
11.8
8.2

51.3
12.1
6.8

54.5
12.4
8.1

3602
3904

50.1
49.9

49.4
50.6

50.5
49.5

49.4
50.6

51.9
48.2

51.2
48.8

50.9
49.1

52.0
48.0

4820
3028

61.1
38.9

61.0
39.0

61.9
38.0

60.3
39.7

62.4
37.6

60.9
39.1

59.6
40.4

61.9
38.1

4911
2937

61.9
38.1

65.2
34.8

62.6
37.1

62.5
37.5

62.7
37.3

63.8
36.2

61.3
38.7

64.0
36.0

4552
3035

50.1
49.9

54.1
45.9

50.2
49.8

53.6
46.4

51.3
48.7

51.7
48.3

53.7
46.3

53.0
47.0

1466
6382

12.6
87.4

15.5
84.5

13.8
86.2

13.5
86.4

15.2
84.8

14.1
85.9

16.3
83.7

12.6
87.4

2800
5048

32.1
67.9

33.3
66.7

31.3
68.7

34.6
65.4

31.2
68.8

33.7
66.3

33.1
66.9

31.3
68.7

1090
3334
3424

8.1
35.9
56.1

11.2
38.5
50.3

9.2
37.1
53.7

9.8
10.4
37.6
38.1
52.6
51.5
Mean ± SD

10.5
36.2
53.3

11.1
39.9
49.0

8.6
35.1
56.4

AGE (years)
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56.9±0. 56.6±0.
56.5±0. 57.8±0. 56.2±0. 58.4±0. 57.1±0.
56.8±0.5
5
6
6
6
6
6
1
BMI (kg/m2)
26.9±0. 27.8±0.
27.7±0. 26.9±0. 27.5±0. 26.9±0. 27.3±0.
27.9±0.2
2
2
2
2
2
2
2
Waist Circumference
94.7±0. 96.6±0. 95.1±0.0 96.4±0. 94.9±0. 95.7±0. 95.4±0. 95.8±0.
(cm)
3
5
3
4
4
4
3
4
High density lipoprotein
51.1±0. 51.2±0.
50.7±0. 51.7±0. 50.8±0. 50.5±0. 50.9±0.
51.5±0.6
(mg/dl)
6
6
6
6
6
5
5
Systolic Blood Pressure
128.9±0 129.9±0 128.7±0. 129.6±0 129.5±0 129.1±0 130.3±0 127.6±0
(mmHg)
.5
.6
6
.6
.6
.7
.7
.4
Diastolic Blood Pressure
75.5±0. 77.3±0.
76.8±0. 75.3±0. 76.6±0. 75.9±1. 76.4±0.
75.7±0.3
(mmHg)
3
3
4
3
3
1
3
Triglycerides (mg/dl)
155.6±2 145.6±3 152.6±2. 151.9±3 152.2±2 149.0±2 155.3±2 150.2±0
.9
.4
3
.1
.2
.9
.6
.5
HbA1c(%)
5.5±0.0 5.6±0.0 5.5±0.03 5.5±0.0 5.6±0.0 5.6±0.0 5.6±0.0 5.6±0.0
Fasting plasma
99.8±0. 103.5±1 101.7±0. 101.8±0 102.7±0 102.1±1 103.9±1 101.3±0
Glucose(mg/dl)
6
.1
8
.9
.9
.1
.1
.9
Fiber Intake (g/day)
16.1±0. 17.0±0.
17.3±0. 16.0±0. 16.9±0. 16.3±0. 16.5±0.
15.8±0.3
3
3
3
3
2
3
3
a
Total numbers may be different due to missing data
b
Income-to-poverty ratio: (midpoint family income)/(poverty threshold values based on calendar years and inflation)
c
Central adiposity present if waist for male subjects ≥101.6 cm and for female subjects ≥88.9 cm

Table 5.2: Correlation between the four Z cluster scores
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OrangeRedYellowOrange-Blue
Red
Green
Orange
0.64**
0.68**
0.34**
Orange-Red
0.91**
0.49**
Red-Green 0.64**
0.68**
0.91**
0.50**
YellowOrange
0.49**
0.50**
Orange-Blue 0.34**
**P Value = <.0001
Orange-Red: P melaninogenica, P intermedia, P nigrescens, P gingivalis
Red-Green: T forsythia, T denticola, A actinomycetemcomitans, E corrodens, S noxia, V parvula, C
rectus
Yellow-Orange: S intermedius, S oralis, S mutans, F nucleatum, M micros, C ochracea
Orange-Blue: E nodatum, A naeslundii

Table 5.3: Mean (Standard Error of Mean) values of serum IgG z-scores of four cluster scores
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Orange-Red

Red-Green

Yellow-Orange

Orange-Blue

-0.25 (0.1)
-0.40 (0.1)
0.09

0.03 (0.4)
-0.16 (0.4)
0.32

0.03 (0.2)
-0.03 (0.2)
0.70

0.05 (0.1)
0.25 (0.1)
0.001

-0.40 (0.1)
-0.28 (0.1)
0.32

-0.17 (0.4)
-0.004 (0.3)
0.43

-0.12 (0.3)
0.07 (0.2)
0.28

0.09 (0.1)
0.18 (0.1)
0.14

-0.34 (0.1)
-0.30 (0.1)
0.74

-0.09 (0.4)
-0.06 (0.4)
0.90

0.01 (0.3)
-0.02 (0.2)
0.90

0.12 (0.1)
0.17 (0.1)
0.42

-0.31 (0.1)
-0.31 (0.1)
0.99

-0.06 (0.4)
-0.02 (0.3)
0.83

0.01 (0.2)
0.04 (0.2)
0.86

0.13 (0.1)
0.17 (0.1)
0.46

-0.08 (0.1)
-0.40 (0.1)
0.0007

0.02(0.4)
-0.1(0.3)
0.41

0.04 (0.2)
-0.01 (0.2)
0.64

0.07 (0.1)
0.19 (0.1)
0.02

0.07 (0.4)
0.09 (0.2)
-0.14 (0.3)
-0.05 (0.2)
0.25
0.34
#Adult Treatment Panel (ATP) III-Criteria
#Elevated Fasting plasma glucose (>110 mg/dl)

0.10 (0.1)
0.18 (0.1)
0.17

Hypertension
Yes (4696)
No (3128)
P value
Hypertriglyceridemia
Yes (2973)
No (4911)
P value
Low HDL- cholesterol
Yes (2934)
No (4820)
P value
Central Adiposity
Yes (3904)
No (3602)
P value
Elevated plasma glucose
Yes (2988)
No (4845)
P value
Metabolic Syndrome
Yes(2867)
No (3829)
P value

-0.21 (0.1)
-0.40 (0.1)
0.04

Yes (1466)
-0.17 (0.1)
-0.3 (0.4)
-0.17 (0.2)
No (6367)
-0.35 (0.1)
-0.03(0.3)
0.03 (0.2)
P value
0.2146
0.2504
0.2727
#Metabolic syndrome
Yes (3277)
-0.25 (0.1)
0.1 (0.4)
0.13 (0.3)
No (4571)
-0.36 (0.1)
-0.15 (0.3)
-0.06 (0.2)
P value
0.26
0.25
0.31
Orange-Red: P melaninogenica, P intermedia, P nigrescens, P gingivalis
Red-Green: T forsythia, T denticola, A actinomycetemcomitans, E corrodens, S noxia, V parvula, C rectus
Yellow-Orange: S intermedius, S oralis, S mutans, F nucleatum, M micros, C ochracea
Orange-Blue: E nodatum, A naeslundii
# Defined as per ATP III criteria

-0.09 (0.1)
0.19 (0.1)
0.0002
0.10 (0.1)
0.17 (0.1)
0.22
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Table 5.4: Odds Ratio (95% CI) between four cluster scores in relation to metabolic syndrome and its individual components
Orange-Red
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Hypertension
Model1
1.02 (1.001-1.05)*
Model2
1.02 (0.99-1.04)
Model3
1.01 (0.97-1.05)
Model4
1.01 (0.97-1.05)
Hypertriglyceridemia
Model1
0.99 (0.97-1.02)
Model2
0.98 (0.95-1.01)
Model3
0.98 (0.94-1.02)
Model4
0.97 (0.94-1.01)
Low HDL-Cholesterol
Model1
0.99 (0.97-1.01)
Model2
0.99 (0.97-1.01)
Model3
0.98 (0.95-1.01)
Model4
0.98 (0.95-1.01)
Central Obesity
Model1
1.003 (0.97-1.04)
Model2
1.02 (0.99-1.05)
Model3
1.01 (0.96-1.07)
Model4
1.01 (0.96-1.06)
Elevated Plasma Glucose
Model1
1.07 (1.03-1.1)*
Model2
1.06 (1.02-1.1)*
Model3
1.06 (1.02-1.1)*
Metabolic Syndrome
Model1
1.02 (1.002-1.04)*

Red-Green

Yellow- Orange

Orange-Blue

1.03 (0.99-1.06)
1.01 (0.98-1.04)
1.02 (0.98-1.05)
1.02 (0.98-1.06)

0.98 (0.95-1.01)
0.99 (0.96-1.04)
0.99 (0.95-1.03)
0.99 (0.95-1.03)

0.91 (0.87-0.95)*
0.95 (0.92-1.00)
0.96 (0.91-1.01)
0.96 (0.92-1.02)

1.01 (0.98-1.04)
1.0 (0.97-1.03)
1.002 (0.96-1.04)
1.01 (0.97-1.05)

0.99 (0.96-1.02)
1.003 (0.97-1.03)
1.01 (0.96-1.05)
1.004 (0.96-1.05)

0.97 (0.93-1.03)
0.99 (0.94-1.04)
0.99 (0.92-1.05)
0.99 (0.92-1.06)

0.99 (0.96-1.03)
0.99 (0.96-1.03)
0.99 (0.96-1.04)
1.002 (0.96-1.04)

1.02 (0.98-1.06)
1.02 (0.98-1.06)
1.01 (0.97-1.06)
1.01 (0.97-1.06)

0.98 (0.94-1.03)
0.98 (0.93-1.02)
0.99 (0.94-1.06)
0.99 (0.94-1.06)

1.00 (0.98-1.03)
0.99 (0.97-1.02)
1.0 (0.95-1.05)
0.99 (0.94-1.05)

1.00 (0.97-1.04)
0.99 (0.96-1.04)
1.02 (0.95-1.08)
1.02 (0.95-1.09)

0.98 (0.94-1.03)
0.99 (0.96-1.04)
0.95 (0.88-1.03)
0.95 (0.88-1.03)

1.01 (0.98-1.04)
0.99 (0.97-1.03)
0.99 (0.96-1.03)

0.97 (0.94-1.001)
0.99 (0.96-1.02)
0.99 (0.96-1.03)

0.94 (0.89-0.98)*
0.97 (0.927-1.02)
0.98 (0.93-1.03)

1.01 (0.99-1.04)

0.99 (0.96-1.02)

0.96 (0.92-0.99)*

Model2
Model3
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1.02 (0.99-1.04)
1.0 (0.97-1.03)
1.00 (0.97-1.04)
0.99 (0.95-1.03)
1.02 (0.99-1.04)
1.003 (0.97-1.04)
0.99 (0.96-1.04)
0.99 (0.94-1.05)
#Adult Treatment Panel (ATP) III-Criteria
Elevated Plasma Glucose
Model1
0.99 (0.96-1.04)
0.99 (0.94-1.04)
1.05 (1.01-1.10)*
0.91 (0.87-0.95)*
Model2
1.04 (0.99-1.10)
0.98 (0.95-1.02)
1.01 (0.96-1.06)
0.94 (0.89-0.98)*
Model3
0.98 (0.94-1.02)
1.02 (0.97-1.07)
1.07 (1.02-1.12)*
0.93 (0.88-0.98)*
Metabolic
Syndrome
Model1
1.004 (0.99-1.02)
1.01 (0.99-1.04)
1.001 (0.97-1.04)
0.95 (0.91-0.99)*
Model2
1.001 (0.98-1.02)
1.001 (0.97-1.03)
1.01 (0.97-1.05)
0.98 (0.94-1.03)
Model3
0.99 (0.96-1.02)
1.002 (0.97-1.03)
1.02 (0.97-1.07)
0.98 (0.92-1.04)
Model1 with no adjustment for confounders;
Model2 adjusted for age (continuous) and sex;
Model3 adjusted further for education, ethnicity, income-to-poverty, smoking, drinking alcohol,
physical activity, BMI (continuous), waist circumference [WC], and dentist visit;
Model4 further for diabetes
* P Value <0.05
Orange-Red: P melaninogenica, P intermedia, P nigrescens, P gingivalis
Red-Green: T forsythia, T denticola, A actinomycetemcomitans, E corrodens, S noxia, V parvula, C rectus
Yellow-Orange: S intermedius, S oralis, S mutans, F nucleatum, M micros, C ochracea
Orange-Blue: E nodatum, A naeslundii
# Defined as per ATP III criteria

Table 5.5: Odds Ratio (95% CI) between four cluster scores in relation to metabolic syndrome and its individual components
among the dentate participants (N=3716)

Orange-Red

152

Hypertension
Model1
Model2
Model3
Model4
Hypertriglyceridemia
Model1
Model2
Model3
Model4
Low HDL-Cholesterol
Model1
Model2
Model3
Model4
Central Obesity
Model1
Model2
Model3
Model4
Elevated Plasma Glucose
Model1
Model2
Model3

Red-Green

Yellow- Orange

Orange-Blue

1.01 (0.97-1.05)
0.99 (0.96-1.04)
0.99 (0.95-1.04)
0.99 (0.94-1.04)

1.02 (0.98-1.06)
1.01 (0.97-1.05)
1.01 (0.97-1.05)
1.01 (0.97-1.05)

0.98 (0.93-1.02)
0.99 (0.95-1.04)
0.99 (0.94-1.06)
0.99 (0.94-1.06)

0.92 (0.87-0.98)*
0.98 (0.92-1.04)
0.98 (0.91-1.05)
0.98 (0.91-1.05)

1.003 (0.97-1.04)
0.99 (0.96-1.03)
1.002 (0.96-1.05)
0.99 (0.95-1.04)

1.02 (0.98-1.06)
1.01 (0.97-1.05)
1.01 (0.97-1.06)
1.02 (0.97-1.06)

0.97 (0.93-1.01)
0.98 (0.95-1.02)
0.99 (0.94-1.03)
0.98 (0.94-1.03)

0.96 (0.90-1.04)
0.98 (0.91-1.06)
0.96 (0.89-1.05)
0.97 (0.89-1.05)

0.99 (0.96-1.02)
0.99 (0.96-1.02)
0.98 (0.95-1.01)
0.97 (0.94-1.01)

1.001 (0.96-1.05)
1.001 (0.96-1.05)
0.99 (0.95-1.04)
0.99 (0.95-1.04)

1.01 (0.96-1.06)
1.01 (0.96-1.06)
1.03 (0.97-1.09)
1.03 (0.97-1.09)

0.97 (0.91-1.04)
0.97 (0.91-1.04)
0.98 (0.91-1.06)
0.98 (0.91-1.07)

1.01 (0.97-1.05)
1.02 (0.98-1.06)
1.03 (0.95-1.11)
1.03 (0.95-1.11)

1.01(0.97-1.04)
1.01 (0.97-1.05)
1.02 (0.95-1.08)
1.01 (0.95-1.08)

0.98(0.94-1.03)
0.98 (0.93-1.02)
0.98 (0.90-1.07)
0.98 (0.90-1.07)

1.01 (0.95-1.07)
1.04 (0.98-1.10)
0.96 (0.87-1.06)
0.96 (0.87-1.06)

1.07 (1.03-1.11)*
1.06 (1.02-1.11)
1.06 (1.02-1.11)*

1.03 (0.97-1.09)
1.02 (0.96-1.08)
1.002 (0.95-1.06)

0.95 (0.89-1.01)
0.96 (0.90-1.03)
0.98 (0.92-1.05)

0.97 (0.91-1.02)
1.01 (0.95-1.07)
1.01 (0.95-1.08)
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Metabolic Syndrome
1.02 (0.99-1.06)
1.03 (0.99-1.07)
0.96 (0.91-1.01)
0.99 (0.93-1.05)
Model1
1.02 (0.99-1.05)
1.02 (0.98-1.06)
0.97 (0.92-1.02)
1.03 (0.97-1.10)
Model2
1.04 (1.001-1.09)
1.02 (0.98-1.06)
0.96 (0.91-1.01)
1.03 (0.96-1.11)
Model3
#Adult Treatment Panel (ATP) III-Criteria
#Elevated Plasma Glucose
1.03 (0.96-1.10)
0.95 (0.89-1.01)
Model1
1.06 (1.01-1.11)*
0.92 (0.88-0.97)*
1.06 (0.99-1.12)
1.01 (0.95-1.08)
0.96 (0.91-1.03)
0.96 (0.92-1.02)
Model2
0.99 (0.94-1.05)
0.98 (0.93-1.04)
0.96 (0.89-1.03)
Model3
1.07 (1.02-1.13)*
#Metabolic
Syndrome
1.02 (0.98-1.06)
0.98 (0.92-1.03)
Model1
1.002 (0.97-1.03)
0.98 (0.92-1.05)*
1.0 (0.97-1.03)
1.01 (0.97-1.06)
0.98 (0.93-1.04)
1.02 (0.96-1.09)
Model2
1.01 (0.97-1.05)
1.002 (0.96-1.05)
0.99 (0.94-1.05)
1.01 (0.93-1.09)
Model3
Model1 with no adjustment for confounders;
Model2 adjusted for age (continuous) and sex;
Model3 adjusted further for education, ethnicity, income-to-poverty, smoking, drinking alcohol,
physical activity, BMI (continuous), waist circumference [WC], and dentist visit;
Model4 further for diabetes
* P Value <0.05
Orange-Red: P melaninogenica, P intermedia, P nigrescens, P gingivalis
Red-Green: T forsythia, T denticola, A actinomycetemcomitans, E corrodens, S noxia, V parvula, C rectus
Yellow-Orange: S intermedius, S oralis, S mutans, F nucleatum, M micros, C ochracea
Orange-Blue: E nodatum, A naeslundii
# Defined as per ATP III criteria

Table 5.6: Odds Ratio (95% CI) between three groups of z-scores in relation to metabolic syndrome and its individual
components

Etiology
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Hypertension
Model1
Model2
Model3
Model4
Hypertriglyceridemia
Model1
Model2
Model3
Model4
Low HDL-Cholesterol
Model1
Model2
Model3
Model4
Central Obesity
Model1
Model2
Model3
Model4
Elevated Plasma Glucose
Model1
Model2
Model3
Metabolic Syndrome

Putative

Health

1.03 (0.99-1.07)
1.04 (0.99-1.04)
1.02 (0.96-1.08)
1.02 (0.96-1.08)

1.00 (0.96-1.04)
0.99 (0.95-1.04)
1.00 (0.95-1.05)
1.00 (0.95-1.05)

0.95 (0.88-1.01)
0.97 (0.90-1.04)
0.98 (0.91-1.07)
0.99 (0.91-1.07)

1.00 (0.96-1.05)
1.01 (0.96-1.05)
1.01 (0.96-1.05)
1.00 (0.96-1.05)

0.99 (0.97-1.02)
0.99 (0.96-1.02)
0.99 (0.96-1.03)
0.99 (0.96-1.03)

0.97 (0.91-1.05)
0.98 (0.91-1.06)
0.99 (0.90-1.08)
0.99 (0.90-1.09)

0.99 (0.94-1.03)
0.99 (0.94-1.03)
0.97 (0.92-1.02)
0.97 (0.92-1.02)

1.03 (1.00-1.07)
1.03 (1.00-1.07)
1.04 (1.00-1.08)
1.04 (1.00-1.08)

0.94 (0.88-1.00)
0.94 (0.88-1.00)
0.97 (0.90-1.04)
0.97 (0.90-1.05)

1.00 (0.96-1.04)
1.00 (0.96-1.04)
0.93 (0.86-0.99)
0.92 (0.86-0.99)

1.01 (0.98-1.04)
1.01 (0.98-1.05)
1.08 (1.02-1.15)
1.08 (1.02-1.15)

0.97 (0.91-1.04)
0.97 (0.92-1.03)
0.94 (0.86-1.03)
0.95 (0.86-1.04)

1.03 (0.99-1.07)
1.03 (0.99-1.07)
1.03 (0.99-1.08)*

1.00 (0.97-1.03)
0.99 (0.97-1.02)
0.99 (0.96-1.03)

0.94 (0.88-1.01)
0.96 (0.89-1.03)
0.98 (0.91-1.07)

155

Model1
1.02 (0.98-1.06)
1.01 (0.98-1.03)
0.96 (0.90-1.01)
Model2
1.02 (0.99-1.06)
1.00 (0.97-1.03)
0.97 (0.91-1.03)
Model3
1.01(0.96-1.06)
1.01 (0.97-1.04)
0.99 (0.92-1.06)
ATP III Criteria
Elevated Plasma Glucose
Model1
1.02 (0.96-1.08)
1.02 (0.97-1.06)
0.89 (0.84-0.95)
Model2
1.02 (0.96-1.09)
1.01 (0.97-1.05)
0.90 (0.84-0.97)
Model3
1.00 (0.94-1.07)
1.02 (0.97-1.07)
0.94 (0.87-1.02)
Metabolic Syndrome
Model1
1.01(0.97-1.05)
1.01 (0.98-1.05)
0.96 (0.91-1.02)
Model2
1.01(0.97-1.05)
1.01 (0.98-1.05)
0.97 (0.92-1.03)
Model3
0.98(0.94-1.03)
1.03 (0.98-1.07)
1.00 (0.92-1.08)
Model1 with no adjustment for confounders;
Model2 adjusted for age (continuous) and sex;
Model3 adjusted further for education, ethnicity, income-to-poverty, smoking, drinking alcohol,
physical activity, BMI (continuous), waist circumference [WC], and dentist visit;
Model4 further for diabetes
* P Value <0.05
Orange-Red: P melaninogenica, P intermedia, P nigrescens, P gingivalis
Red-Green: T forsythia, T denticola, A actinomycetemcomitans, E corrodens, S noxia, V parvula, C rectus
Yellow-Orange: S intermedius, S oralis, S mutans, F nucleatum, M micros, C ochracea
Orange-Blue: E nodatum, A naeslundii
# Defined as per ATP III criteria
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CHAPTER 6
DISSERTATION SUMMARY
Periodontal disease, a polybacterial infection, is associated with different systemic
diseases including hyperglycemia and cardiovascular risk factors. From the literature,
there is emerging evidence that effect of periodontal infection on cardiovascular
outcomes depends upon the type of bacteria predominating the infection(Desvarieux et al.
2013, Desvarieux et al. 2010, Desvarieux et al. 2005, Ebersole et al. 2008, Kebschull,
Demmer, and Papapanou 2010, Lockhart et al. 2012), but this has not been evaluated for
type 2 diabetes thoroughly. However, the microbiological evidence supports that
periodontal bacteria or their antibodies are associated with diabetes(Casarin et al. 2013,
Field et al. 2012, Ohlrich, Cullinan, and Leichter 2010, Vlachojannis et al. 2010, Yuan et
al. 2001, Zhou et al. 2013).
There are several questions but a dearth of knowledge in the area of periodontal
research in relation to the systemic outcomes. Through our dissertation research
questions, we have tried to find some answer for some of gaps that existed in the
periodontal research with a systemic association such
1. How will we characterize the polybacterial infection or the antibody response of the poly
bacterial challenges through the biofilm?
2. What is the extent of association of the elevated antibody titers that formed due to
specific periodontal bacteria with respect to T2DM, pre-diabetes and Mets and each of its
individual components?
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3. Does periodontal destruction modify the association of host response against the
periodontal bacteria and diabetes?
We characterized the antibody response of the polybacterial challenges by using
both the data derived clustering approach and the theoretical grouping approach. From
the empirical approach, we found that the predominance of the elevated serum IgG
Orange-Red cluster that included P gingivalis and Prevotella sps was associated with
higher diabetes prevalence whereas elevated Orange-Blue clusters that included the E.
nodatum and A neslundii antibodies lowered the odds of having type 2 diabetes , while
predominance of the elevated Red-Green cluster that included A. actinomycetemcomitans
mix, S. noxia, E. corrodens, V. parvula, T. forsythia, T. denticola, C. rectus antibodies
was slightly associated with lower odds of having diabetes. Yellow-orange cluster which
consist majority of Streptococcus sps antibodies were not associated with diabetes or prediabetes. From the theoretical grouping approach, we found the elevated etiologic group
that consists P gingivalis, A. actinomycetemcomitans mix, T. forsythia, and T. denticola,
to be mainly associated with pre-diabetes condition while the putative or Health related
groups were not associated with diabetes, pre-diabetes , MetS or any of its individual
components.
Mainly our study finding shows that serological markers of periodontal bacteria
are related to diabetes prevalence and monitoring the type of periodontal bacteria
antibodies in the serum may be important in finding the individuals with high risk of
diabetes and pre-diabetes. Combination of clinical periodontal destruction measures and
serological markers can provide more information on the hyperglycemia condition.
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Strengths and Limitations
There were several strengths in this study. First, plasma IgG antibodies against the
periodontal pathogen of A Actinomycetecomitans and P. gingivalis have been found to be
stable for 15 years (Lakio et al. 2009). IgG antibodies against periodontal pathogen
therefore represent the cumulative lifetime infection of periodontal disease and host
response towards it. Second, we had enough power, sample size and data on serum
antibodies of 19 different periodontal bacteria to analyze on the immune -inflammatory
response to these periodontal bacteria in relation to diabetes, pre-diabetes as well as other
key markers of cardiovascular risk factors adjusting for known confounders. Third, large
sample size and clustering of serum IgG markers reduced the chances of type 1 error and
gave confidence in the interpretation of the findings. We believe that this study will
provide a perspective to understand the magnitude of host immune response to different
periodontal bacteria in different clinical biomarkers of inflammatory diseases.
However, our study also has some drawbacks. First, it should be noted that our
study being a cross sectional study cannot identify temporality or causality. Studies
evaluating the accuracy of the dental examination in NHANES III and NHANES (20012004) showed that periodontitis prevalence was underestimated in of in those surveys
because of the examination protocol and periodontal disease definitions that were used
which may impact validity in surveillance and researches (Eke et al. 2010). Third, our
study dataset includes information from 1988 -1994, the smoking habits, nutritional
behaviors, diabetes awareness might have changed amply since then, hence the external
validity of the findings should be assessed with more current information (Dye, Morin,
and Robison 2006, Dye et al. 2007, Morin, Dye, and Hooper 2005). Fourth, there were
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many missing data (about 25%) for the CAL and pocket depth which might have
underestimated the estimation of interaction between the clusters and clinical periodontal
measures with diabetes. Fifth, the periodontal examination was done not done on the full
mouth in NHANES III survey which might have also under estimated the prevalence of
periodontitis in the US population(Papapanou 2012).
Clinical Implication of our study and Recommendation to the clinicians
Our findings have a strong implication for clinical management of high risk
population for diabetes and periodontal disease. Elevated serum antibody titers of
selective periodontal bacteria (such as P. gingivalis and Prevotella sps.) could increase
the odds of having diabetes. The presence of elevated titers of Orange-Blue cluster could
significantly reduce the odds of having diabetes even in the presence of higher pocket
depth destruction. This suggests that combination of serological markers and clinical
periodontal measures may be useful to predict the hyperglycemia condition. Dental visits
combined with the test of selected serological markers such as P gingivalis, Prevotella
species, E nodatum and A neslundii may be used to screen the high risk individuals for
the diabetes or pre-diabetes.
Recommendation to the public health professions
In recent years, the prevalence of chronic diseases such as type 2 diabetes,
obesity, hypertension, lipidemia, MetS are in increasing. Oral health can be important
lifestyle modulator that is associated with diabetes risk and can also be used to predict the
risk of systemic health of an individual. More research is necessary to understand the
biological pathways for the association of periodontal disease with different chronic
systemic outcomes. Several evidences support that oral infection that is often hidden and
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neglected and could be one of seeds of infection that can ultimately lead to systemic
inflammation which is the key of several chronic systemic diseases including
hyperglycemia. Hence, we recommend that Oral health is a priority in the research and
policy of overall public health.
Current work and suggestions for future research
All of the aims encompassed by my dissertation relate to US participants. This is
the first attempt to cluster the antibody titers against periodontal bacteria and explore
these clusters in relation to systemic outcomes. We found the specific serological markers
are associated with a protective role or potential risk of systemic diseases while some are
unrelated. We would like emphasize that further research with new sophisticated
molecular technology, epidemiological methods and clinical periodontal examination in
the recent population are needed to validate our findings in different population.
Recent reports of gut microbiota being associated with diabetes, MetS and other
systemic conditions such as obesity strengthens the possibility of linkage of periodontal
bacteria (Zupancic et al. 2012) and underscores the need of further research to identify
the systemic pathways. Future research could explore the correlation of the gut
microbiota with periodontal microbiota. Further exploration of the inter-relationship with
the systemic outcomes could characterize the microbiota role in systemic health.
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APPENDIX A – PERIODONTAL CLINICAL MEASURES AND FOUR CLUSTERS
Table A.1: Association of the z-scores of serum antibody clusters with diabetes stratified
by the periodontal status
Serum Antibody
Odds Ratio (95% Confidence Interval)
z-scores Clusters
Periodontal status
Model*
Yes
No
Red-Green
Model1
1.03 (0.95, 1.11)
1.02 (0.93, 1.11)
Model2
1.00 (0.92, 1.09)
1.03 (0.93, 1.13)
Model3
1.01 (0.92, 1.10)
1.00 (0.92, 1.09)
Model4
0.99 (0.87, 1.12)
1.00 (0.92, 1.10)
Orange-Red
Model1
1.12 (1.03, 1.22)
1.14 (1.05, 1.25)
Model2
1.01 (0.92, 1.12)
1.09 (1.00, 1.20)
Model3
1.01 (0.90, 1.14)
1.10 (1.00, 1.21)
Model4
0.91 (0.81, 1.12)
1.14 (1.02, 1.27)
Yellow-Orange
Model1
0.96 (0.86, 1.06)
0.95 (0.86, 1.06)
Model2
1.00 (0.90, 1.11)
0.98 (0.88, 1.08)
Model3
0.98 (0.88, 1.10)
1.01 (0.93, 1.11)
Model4
1.04 (0.89, 1.21)
1.06 (0.94, 1.18)
Orange-Blue
Model1
0.83 (0.74, 0.92)
0.86 (0.75, 0.98)
Model2
0.98 (0.85, 1.13)
0.85 (0.76, 0.95)
Model3
0.95 (0.82, 1.12)
0.85 (0.76, 0.95)
Model4
0.93 (0.77, 1.13)
0.75 (0.64, 0.88)
*Bold p value <0.05
Model1 with no adjustment for confounders; Model2 adjusted for age (continuous), sex,
education, ethnicity, income-to-poverty; Model3 adjusted further for smoking and
drinking alcohol; Model4 further for physical activity, BMI (continuous), waist
circumference [WC],dentist visit and fibers intake.
Orange-Red: P. melaninogenica, P. intermedia, P. nigrescens, P. gingivalis
Red-Green: T. forsythia, T. denticola, A. actinomycetemcomitans, E. corrodens, S. noxia,
V. parvula, C. rectus
Yellow-Orange: S. intermedius, S. oralis, S. mutans, F. nucleatum, M. micros, C.
ochracea
Orange-Blue: E. nodatum, A. naeslundii
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